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ABSTRACT 
Periodontitis and rheumatoid arthritis (RA) are both widespread multifactorial diseases, 
characterized by chronic inflammation leading to tissue and bone destruction around teeth or 
joints, respectively. An association between periodontitis and RA has been proposed, 
suggesting that the periodontal pathogen Porphyromonas gingivalis (P. gingivalis) may be 
involved in the generation of anti-citrullinated protein antibodies (ACPAs) in RA. Previous 
findings indicate that patients with RA may have increased prevalence/incidence and severity of 
periodontitis; however, more studies are needed to confirm this link, elucidate the potential 
mechanisms involved, and ascertain the temporal relationship between periodontitis and RA. 
Hence, the general aim of this thesis was to study the relationship between periodontitis and RA 
using population-based, clinical, immunohistochemical and experimental animal studies.  
Study I investigated the prevalence of periodontitis with special focus on ACPA status in the 
Swedish Epidemiological Investigation of RA (EIRA), a well-characterized population-based 
RA case-control cohort. Linking the EIRA registry with the Dental Health Registry (DHR) 
demonstrated no differences in the prevalence of periodontal diseases (gingivitis, periodontitis, 
or peri-implantitis) between RA patients and matched healthy controls. Additionally, among 
subjects with RA, we detected no differences in prevalence of periodontitis based on ACPA or 
rheumatoid factor (RF) antibody status.  
Study II explored the effect of pre-existing periodontitis on the development and the 
immune/inflammatory response of experimental arthritis in an animal model. Eight weeks prior 
to induction of pristane-induced arthritis, we induced experimental periodontitis in arthritis-
susceptible Dark Agouti rats using ligatures in combination with swabs containing periodontal 
bacteria. After monitoring the progression and severity of both periodontitis and arthritis for 
another 7 weeks, we compared the results to animals with experimental arthritis only and to 
healthy animals without arthritis or periodontitis. We detected increased levels of antibodies 
against citrullinated P. gingivalis peptidylarginine deiminase (PPAD) proteins in rats with both 
pre-existing periodontitis and pristane-induced arthritis compared to arthritic animals without 
pre-existing periodontitis. However, the pre-existence of periodontitis did not affect the 
development or severity of pristane-induced arthritis in rats. 
Study III examined the presence of citrullinated proteins and the expression of human 
peptidylarginine deiminase (PAD2 and PAD4) enzymes in relation to the presence of P. 
gingivalis in gingival tissue biopsies from patients with periodontitis and healthy controls. In 
gingival connective tissue, we detected citrullinated proteins in 80% of the subjects with 
periodontitis compared to in 25% of healthy controls. Analysis of the sections also showed 
increased expression of PAD2 and PAD4 in the gingival connective tissue of patients with 
periodontitis. We found no differences in the presence of P. gingivalis in the epithelium or 
connective tissue of gingival biopsies from patients with periodontitis and healthy controls 
without periodontitis. Moreover, we observed no correlations between the presence of P. 
gingivalis and citrullinated proteins or citrullinating enzymes in gingival tissue from patients 
with periodontitis and healthy controls. 
  
Study IV was a clinical study that further explored the association between RA and the severity 
of periodontitis. This pilot study aimed to investigate the severity of periodontitis in relation to 
ACPA/RF status, immunological parameters associated with RA, and the presence of 
subgingival P. gingivalis DNA in patients with established RA. The findings showed that the 
majority of patients with RA had moderate/severe periodontitis (75%), while the others had 
no/mild periodontal disease. ACPA positivity was significantly more common in RA subjects 
with moderate/severe periodontitis compared to those with no/mild periodontal disease. We 
detected no differences in the presence of P. gingivalis in subgingival plaque samples based on 
periodontitis severity or ACPA status. Nor did we detect any between-group differences in RA 
disease duration or disease activity or type of RA treatment/medication. Cytokine profiling of 
serum, saliva, and gingival crevicular fluid samples showed that the levels of several 
inflammatory mediators were up-regulated in patients with moderate/severe periodontitis. 
Interestingly, the levels of a proliferation-inducing ligand (APRIL), implicated in B-cell survival 
and maturation, were significantly higher in both serum and saliva samples of patients with 
moderate/severe periodontitis compared to those with no/mild periodontal disease.  
In conclusion, we found no evidence of an increased prevalence of periodontitis in patients with 
established RA relative to healthy controls, in the large population-based registry study. 
However, the clinical study showed that the more severe forms of periodontitis, defined as 
moderate/severe periodontitis, were frequent in subjects with established RA, and associated 
with ACPA positivity. Our findings also demonstrate that the presence of citrullinated proteins 
and expression of human citrullinating PAD enzymes are increased in gingival tissue of non-RA 
subjects with chronic periodontitis, and that the pre-existence of periodontitis can induce a 
systemic antibody response against citrullinated proteins derived from P. gingivalis PAD 
enzyme in animals with experimental arthritis. Taken together, the results indicate that 
periodontal infection could possibly contribute to the autoimmunity against citrullinated 
proteins associated with RA. Since ACPA status may be associated with periodontitis severity, 
future studies on the association between periodontitis and RA should focus on investigating the 
potential beneficial effects of periodontal treatment in patients with RA. Moreover, additional 
research into predisposing risk factors and molecular mechanisms connecting periodontitis with 
RA are also warranted. 
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eriodontitis and rheumatoid arthritis (RA) are both widespread chronic inflammatory 
diseases that destroy bones and supporting structures around teeth or joints, respectively, 
and can lead to permanent disability. These two inflammatory conditions share etiological 
and pathogenic features, such as similar cytokine profiles and smoking as a major risk factor. 
Previous studies have proposed an association between RA and periodontitis, although the 
strength and temporality of this association is still unclear. The following summary includes a 
brief background of periodontal disease and RA (including a short introduction to the 
anatomy of the periodontium and the joint), similarities between periodontitis and RA, the 
potential bacterial link, as well as an overview of previous studies conducted on the 
relationship between these two diseases. 
 
THE PERIODONTIUM 
The periodontium refers to the tissues supporting the teeth, and is also known as the tooth’s 
“attachment apparatus” [1]. It involves the gingiva, the periodontal ligament, the root 
cementum as well as the alveolar bone, described in detail below (Figure 1) [1]. A 
periodontitis affected periodontium is characterized by an accumulation of inflammatory cells 
in the tissues adjacent to the tooth, a breakdown of the collagen fibers connecting the root 
cementum to the connective tissue and bone, a subsequent pocket formation and apical 
migration of the junctional epithelium, as well as resorption of the marginal alveolar bone [2]. 
Gingiva 
The gingiva is the part of the oral mucosa that surrounds the alveolar process and the tooth’s 
cervical parts, and can be divided into free or attached gingiva (Figure 1) [1]. Microscopically 
the free and attached gingiva consists of an outer layer of epithelium (oral epithelium, 
sulcular epithelium or junctional epithelium) and an inner layer of connective tissue (Figure 
1) [1]. 
Gingival epithelium 
The gingival epithelium located nearest to the oral cavity is called the oral epithelium 
(depicted as OE in Figure 1), and is mostly (90%) comprised of keratin-producing cells. 
Other cell types found in the oral epithelium are melanocytes (pigment-synthesizing cells), 
Langerhans cells (involved in an early immunological response to the antigens/pathogens 
trying to penetrate the epithelium), Merkel´s cells (believed to have sensory functions) and 
inflammatory cells [1]. The sulcular epithelium (depicted as SE in Figure 1), located at the 
groove between the top of the gingiva and the enamel, is an extension of the oral epithelium 
and is not in contact with the tooth’s surface. Unlike the oral epithelium, this sulcular 
epithelium is non-keratinized and mostly consists of cube-like cells [1]. The junctional 
epithelium (depicted as JE in Figure 1) is the contact point between the tooth and the gingiva 
[1]. It mainly consists of a basal/suprabasal cell layer, but also contains hemidesmosomes  
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physically attaching the epithelium to the tooth. Moreover, white blood cells can also present 
in the wide intercellular space of this epithelium, as they travel towards the gingival sulcus 
[1]. In periodontitis the junctional epithelium proliferates downwards along the surface of the 
root, extending finger-like projection of the pocket epithelium (which is not attached to the 
root surface) into the connective tissue [2]. 
Gingival connective tissue 
The connective gingival tissue (depicted as CT in Figure 1) represents the largest part of the 
gingiva [1]. It predominantly consists of collagen fibers (60%), followed by blood vessels and 
nerves (35%) as well as fibroblasts (5%). Four types of cells are commonly found in the 
connective gingival tissue: fibroblasts which are involved in the production of collagen fibers 
and synthesis of the tissue matrix, mast cells that create some parts of the tissue matrix and 
produce vasoactive substances affecting blood flow in the tissue, macrophages which have 
both a phagocytic and synthesizing role in the connective tissue as well as inflammatory cells 
(including lymphocytes, neutrophils and plasma cells). Both macrophages and inflammatory 
Figure 1.
The tissues supporting the teeth include the gingiva, the periodontal ligament, the root cemen-
tum and alveolar bone. In periodontally healthy individuals, the free gingiva covers the tooth
enamel and is normally coral pink. The attached gingiva firmly covers the alveolar bone and the
root cementum via connective tissue fibers. It is also coral pink in healthy individuals, and
extends from the cementoenamel junction in an apical direction towards the loosely bound
alveolar mucosa. Microscopically the gingiva consists of an outer epithelial layer and an inner
layer of connective tissue.
OE, oral epithelium; SE, sulcular epithelium; JE, junctional epithelium; CT, connective tissue.
Illustration by Igor Kraszewski and Kaja Eriksson.
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cells are involved in the hosts immune-inflammatory defense system against periodontal 
pathogens [3]. Lymphocytes (T- and B-cells) for example can provide an immune defense 
against these pathogens by producing antibodies and inflammatory mediators that neutralize 
extracellular infectious agents, and activate neutrophils and macrophages that can digest the 
bacteria and produce toxic products neutralizing intracellular infectious agents [2, 4].  
Periodontal ligament 
The periodontal ligament (Figure 1) is the tissue that connects the tooth to the alveolar bone, 
through bundles of collagen fibers attaching to the root cementum and the alveolar wall 
socket [1]. In addition, the periodontal ligament contains cells involved in the formation of 
cementum and bone, cementoblasts and osteoblasts, as well as fibroblasts, epithelial cells, 
nerve fibers and bone resorbing osteoclasts. Blood and lymphatic vessels in the periodontal 
ligament supply the tissue with nutrients and remove by-products following metabolism [3]. 
The periodontal ligament is fundamental for tooth mobility including the absorbance and 
distribution of forces elicited during loading/eating etc [1]. 
Root cementum 
The root surface is cover by the root cementum, a thin mineralized layer attaching the 
periodontal ligament to the root [1]. It consists of collagen fibers surrounded by an organic 
matrix, and is a relatively porous tissue. If root cement gets exposed to the oral cavity, toxins 
from the dental plaque can penetrate the cementum, preventing the periodontal ligament from 
attaching [3]. During mechanical periodontal treatment, the root cementrum is removed and 
the exposed root surface may result in sensitivity of the tooth [3]. These symptoms are often 
reversible as new cementum is constantly being synthesized by cementoblasts [3].  
Alveolar bone 
In periodontally healthy individuals the alveolar bone is normally located approximately 2 – 3 
mm apically of the cementoenamel junction (CEJ), following its outline [3]. It consists of an 
outer layer of compact bone, and a more porous inner layer containing bone marrow [3]. 
Cells important for bone remodeling (osteoblasts, osteoclasts and osteocytes) are present in 
the alveolar bone as it is constantly being remodeled to adjust to the mechanical loading and 
to repair minor damages (e.g. microfractures) [3]. In periodontitis, however, local stimuli 
from microbial and host-derived factors, including different inflammatory mediators, 
stimulate the bone resorbing osteoclast ultimately leading to the loss of alveolar bone [5, 6]. 
 
THE JOINT 
A joint is a junction or a connecting point at which two bones come together [7]. The joints 
main functions include holding the skeleton together and allowing movement. Joints can be 
classified according to their mobility (immovable/synarthrotic, slightly 
movable/amphiathrotic or freely movable/diarthrotic) or the type of material they consist of 
that bind the bones together (fibrous, cartilaginous or synovial) [7]. Most of the joints in the  
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body are synovial joints, which are diarthrotic [7]. These consist of an outer joint capsule (a 
layer of ligaments) and an inner synovial membrane, some also including elastic 
fibrocartilage pads which act like cushions protecting the bone during movement (Figure 2). 
Some synovial joints, such as elbows and knees, also have bursae (fluid-filled sack-like 
cavities) situated nearby between muscles/tendons and bone to facilitate gliding and 
movement [7].  
 
Osteoclast
Fibrolast
Macrophage
Dendritic cell
T-cell
Plasma cell
B-cell
Extensive
angiogenesis
Mast cell
Hyperplastic
synovial lining
Pannus
Capsule
Synovium
Neutrophil
Cartilage
Synoviocytes
Bone
HEALTHY JOINT ARTHRITIC JOINT
Figure 2.
The synovial joint is composed of two adjacent bones covered with a layer of cartilage, separated
by a joint space and surrounded by the synovial membrane and joint capsule. The synovial
membrane consists of a thin layer of synoviocytes (macrophage and fibroblast derived). Only a
few, if any, mononuclear cells are interspersed in the sublining connective tissue layer, which has
considerable vascularity. An arthritic joint, e.g. in RA, is initially characterized by an inflammatory
response of the synovial membrane ('synovitis') that is conveyed by a transendothelial influx
and/or local activation of a variety of mononuclear cells, such as T-cells, B-cells, plasma cells,
dendritic cells, macrophages, mast cells, as well as by new vessel formation. The lining layer
becomes hyperplastic and the synovial membrane expands and forms villi. The bone destructive
portion of the synovial membrane is termed 'pannus', and the destructive cellular element is the
osteoclast; destruction mostly starts at the cartilage–bone–synovial membrane junction. Bone
repair by osteoblasts usually does not occur in active RA. Polymorphonuclear leukocytes are
found in high numbers in the joint fluid, but very rarely are seen in the synovial membrane,
suggesting very rapid transgression from blood to the joint space. The neutrophils' enzymes,
together with enzymes secreted by synoviocytes and chondrocytes, lead to cartilage degradation.
Adapted by permission from Macmillan publishers Ltd: Nature Reviews Drug Discovery (Smolen
and Steiner 2003)[9], copyright (2003).
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In a healthy synovial joint the inner layer of the capsule, the synovial membrane, secretes 
synovial fluid thereby lubricating the joint and supplying nutrition to the capsule [7, 8]. The 
synovial membrane is composed of a vascularized loose connective tissue, where the layer 
closest to the cartilage and bone is made up of macrophage- and fibroblast-derived 
synoviocytes (Figure 2) [9]. During an inflammatory stage, such as RA, the synovial 
membrane is infiltrated by various types of immune cells including T-, B- and plasma cells 
(from the adaptive immune system), as well as mast cells, dendritic cells and macrophages 
(from the innate immune system) (Figure 2) [10]. Moreover, the macrophage-like and 
fibroblast-like synoviocytes produce cytokines and proteases, collectively contributing to the 
inflammation and cartilage and bone destruction in RA [8]. During this inflammatory process 
activated fibroblasts, T- and B-cells (which express the receptor activator of nuclear factor κ 
B ligand, RANKL) interact with macrophages, monocytes and dendritic cells (which express 
the receptor RANK) to promote the generation of bone resorbing osteoclast [10]. Meanwhile 
matrix metalloproteinases (MMPs) together with additional metalloproteinase-enzymes (e.g. 
membrane-type metalloproteinases, MT-MMPs) contribute to cartilage destruction [10, 11]. 
 
PERIODONTAL DISEASE 
Periodontal disease includes both reversible and irreversible conditions, where the milder 
reversible forms comprise inflammation of the gingival tissue (gingivitis), and the irreversible 
chronic inflammation (periodontitis or peri-implantitis) causes destruction in connective 
tissue and loss of alveolar bone [6]. 
Gingivitis 
The reversible form of periodontal disease, gingivitis, does not include any destruction of the 
connective tissue or bone [1, 12]. In gingivitis, the inflammation of the gingival tissue can be 
plaque (bacteria) or non-plaque induced (e.g. viral infections, allergies), with the plaque 
induced form being the most common [3, 12]. The diagnosis is based on clinical features 
including swelling, redness and bleeding of the gingival tissue [1]. This condition can be 
reversed by treatment and optimization of oral hygiene [1].  
Periodontitis 
Periodontitis, a major cause of tooth loss in adults, is one of the world’s most prevalent 
chronic infectious inflammatory diseases, affecting up to 25 - 40% of the population [13-15]. 
The most severe form of the disease, ultimately resulting in the loss of teeth, affects 5 - 15% 
of the global population [13, 14]. Diagnosis of periodontitis is based on outcomes from intra-
oral and radiographic examination [1, 12], including assessment of bleeding on probing 
(BOP), probing pocket depth (PPD), clinical attachment level (CAL), alveolar bone level and 
tooth mobility [16]. Chronic periodontitis is classified according to extent (localized or 
generalized) and severity (slight, moderate or severe) of the disease, based on number of sites 
with PPD and/or CAL (Table 1) [12, 16]. Different classifications for periodontal disease      
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have been recommended over the years and the classifications currently in use are based on 
the International Consensus Report on Chronic Periodontitis [12, 16]. 
Chronic periodontitis is initiated by the presence of a microbial biofilm (dental plaque), 
which accumulates around the gingival margin [1, 17]. The first microbial species to colonize 
usually include the Gram-positive Actinomyces and Streptococcus [17]. As the plaque 
continues to accumulate the environment becomes more anaerobic and the biofilm extends 
deeper into the gingival sulcus [1, 17]. In severe periodontitis, this biofilm includes high 
proportions of Gram-negative anaerobic periodontal pathogens [Treponema denticola (T. 
denticola), Tannerella forsythia (T. forsythia) and Porphyromonas gingivalis (P. gingivalis)] 
also referred to as the red complex, additional organisms believed to facilitate the red 
complex colonization (e.g. Fusobacterium nucleatum) as well as other periodontitis 
associated pathogens such as Aggregatibacter actinomycetemcomitans (A. 
actinomycetemcomitans) [1, 18, 19]. In susceptible individuals, the bacterial dysbiosis may 
lead to a chronic inflammation and the development of periodontitis [19]. The progression 
and the disease susceptibility is dependent upon several factors including genetic and 
environmental risk factors (e.g. smoking) and systemic health status that influence the host 
inflammatory response (Figure 3) [19, 20]. Periodontal pathogens from the oral biofilm can 
trigger the inflammatory response resulting in a release of various cytokines and 
inflammatory mediators including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor 
alpha (TNF-), prostaglandin E2 (PGE2), and MMPs, collectively contributing to the 
destruction of tooth-supporting structures [6, 20]. Currently, the main therapy for periodontal 
treatment is to control the oral biofilm by improving oral hygiene and removing plaque and  
Table 1. International consensus criteria for classification of chronic periodontitis 
 
 
 
 
 
 
 
 
 
 
 
    
CAL, clinical attachment level; PPD, periodontal pocket depth. 
Classification according to Case definition 
Armitage 1999 [12] 
“Development of a Classification System 
for Periodontal Diseases and Conditions” 
Extent Localized ≤ 30% of the sites affected 
Generalized > 30% of the sites affected 
                   Severity Slight 1 - 2mm CAL 
  Moderate 3 - 4mm CAL 
 
 Severe ≥ 5mm CAL 
 
Page and Eke 2007 [16] 
“Case Definitions for Use in Population- 
Based Surveillance of Periodontitis” 
No/mild periodontitis Not fulfilling criteria for moderate or 
severe disease 
 
 
Moderate periodontitis  ≥ 2 interproximal sites with CAL ≥ 4mm 
 (not on the same tooth) 
 
   or 
    
≥ 2 interproximal sites with PPD ≥ 4mm  
 (not on the same tooth) 
 
  
Severe periodontitis ≥ 2 interproximal sites with CAL ≥ 6mm 
 (not on the same tooth) 
 
   and 
    
≥ 1 interproximal sites with PPD ≥ 5mm  
(not on the same tooth) 
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dental calculus [21]. Up to date, there are no clinically available biomarkers for periodontitis, 
but understanding how oral pathogens misdirect the host immune response could potentially 
reveal new therapeutic targets for the disease [21, 22]. Periodontitis may also affect the 
general health, for example poor glycemic control has been reported in diabetic patients with 
periodontitis [23]. In addition, patients with periodontitis have increased prevalence and/or 
risk of systemic diseases including cardiovascular disease, diabetes and RA [23-26]. 
Peri-implantitis 
Peri-implantitis is defined as an inflammatory process around a functional implant, associated 
with both soft-tissue inflammation and loss of supporting bone [27]. The diagnosis is made 
based on results from a clinical and radiographic examination, including manifestations of 
swelling, redness, BOP and radiographic loss of bone usually in a shape of a crater around the 
implant [28]. The prevalence of peri-implantitis differs between studies but has been 
estimated to affect approximately 20 - 56% of patients after 1 - 10 years post-implant 
placement [27, 28]. Peri-implatitis is a multifactorial disease where both surgical-, prosthetic- 
and patient-related factors may contribute to its development and severity [27]. This disease 
shares several similarities with periodontitis  including  risk indicators such as smoking, 
diabetes and poor oral hygiene [28, 29]. Peri-implantitis, like periodontitis, is initiated by an 
accumulation of dental plaque containing a large amount of Gram-negative anaerobic 
 9 
 
bacteria (e.g. P. gingivalis, A. actinomycetemcomitans, T. denticola and T. forsythia), 
adjacent to the implant [30]. However, also Staphylococcus aureus, a Gram-positive species 
not associated with periodontitis, has been implicated in the pathogenesis of peri-implant 
disease [30]. The plaque accumulation/bacterial infection adjacent to the implant can trigger 
an inflammatory response in the surrounding tissues, resulting in loss of supporting bone 
(past the normal bone remodeling) [27, 30]. If peri-implantitis is left untreated this 
inflammatory disease may ultimately bring about the loss of the implant [27, 30]. Similar to 
periodontitis, the treatment of peri-implantitis aims to control the infection trough 
improvement of the oral hygiene, mechanical elimination of plaque and dental calculus, and 
detoxification of the surface of the implant [28, 30].  
 
RHEUMATOID ARTHRITIS 
RA is a painful and disabling systemic chronic inflammatory autoimmune disease [31, 32], 
affecting almost 1% of the world population, predominately women [32-34]. It is associated 
with long term morbidity and early mortality despite antirheumatic treatment [32]. This 
chronic inflammatory condition can lead to joint destruction and has also been associated 
with systemic complications (pulmonary, ocular, neurological) as well as cardiovascular 
comorbidity and type 1 diabetes [35-39]. In addition, an association between periodontitis, 
and RA has also been suggested [40]. The etiology of RA is still unknown but is suggested to 
be a combination of genetic, environmental, hormonal and infectious risk factors [32, 40, 41]. 
RA is characterized by synovial joint inflammation and pannus (hypertrophied synovium) 
formation leading to irreversible destruction of cartilage and underlying bone (Figure 2) [38]. 
The joint inflammation is associated with an infiltration of inflammatory cells (such as T- and 
B-cells, macrophags etc) into the synovium as well as a hyperplastic expansion of the 
synovial membrane/synovial cells (fibroblast-like and macrophage-like synoviocytes) 
resulting in production of cytokines and proteases [8, 10, 42]. The overproduction of pro-
inflammatory cytokines (e.g. TNF-) is central to RA pathogenesis,  driving joint destruction 
by stimulating synovial fibroblasts and chondrocytes (cartilage cells) to secrete collagen 
degrading enzymes, as well as by activating osteoclast differentiation, ultimately leading to 
bone and cartilage destruction [35, 43]. In addition, a recent study suggests that anti-
citrullinated protein antibodies (ACPAs) may also contribute to joint destruction in RA [44]. 
The diagnosis of RA is made according to the American College of Rheumatologys (ACR) 
classification criteria using the combination of results from physical examination 
(swelling/arthritis in joints, duration of symptoms) and blood tests [presence of ACPAs 
and/or rheumatoid factor (RF) antibodies, abnormal acute phase reactants such as C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR)], as well as radiographic changes 
[45, 46]. The patient’s functional status is traditionally assessed by a self-administered Health 
Assessment Questionnaire (HAQ), while the disease activity in RA is assessed by a Disease 
Activity Index, for example the Disease Activity Score including 28-joint count (DAS28) 
[31, 47]. The DAS28 score is widely used in clinical assessment of RA disease activity, as 
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well as in research and clinical trials [31, 47, 48]. It is calculated based on the physical 
examination of the number of  swollen and tender joints (hands, arms and knees), the 
patient´s global assessment/general health measured on a visual analog scale (VAS, 0 - 100) 
and measurements of  ESR or CRP (DAS28 CRP) [47]. The disease course in RA can exhibit 
two different patterns; a chronic-persistent affecting 20 - 44% [49-52], or a relapsing-
remitting affecting 7 - 79% of patients with RA [49, 51, 53-55]. Remission without RA-
medication is possible, although sustained remission beyond 1 year is uncommon in patients 
with RA [54, 56]. 
The management of RA includes medication, physical therapy and surgery, and aims to 
relieve symptoms, slow down joint damage and achieve remission [57]. Analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs) reduce joint pain and stiffness [57]. The 
cornerstone in treatment of RA is, however, the use of disease-modifying antirheumatic drugs 
(DMARDs), which reduce the joint inflammation and limit or prevent joint damage [57-59]. 
Non-biological DMARDs (such as methotrexate, sulfasalazine, hydroxychloroquine and 
leflunomide) and biological DMARDs (such as TNF- and IL-6 inhibitors and T- and B-cell 
target therapies), alone or in combination, are demonstrated highly effective in placebo-
controlled trials [57, 58, 60]. Moreover, glucocorticoids can also be used in combination with 
DMARDs to “bridge the patient” until the onset of the therapeutic effect of DMARDs, and 
have also been recommended if the disease activity flares in patients with established RA that 
are already on DMARD/biological DMARD therapy [59, 61]. However, many of these 
medications have side effects including nausea, hypertension, osteoporosis, increased risk of 
infection and peptic ulcers [57, 62]. The specificity and regulation of the underlying 
autoimmune reactions in RA have for long been unclear, preventing a deeper understanding 
of disease processes and the development of new therapies. The discovery of ACPAs, 
however, has given new opportunities and biological tools to design novel models of etiology 
and therapy strategies in RA. 
The ACPA antibodies are specific serological markers for RA, detected in approximately 
70% of patients [19, 63]. These antibodies were first described in 1964, as anti-perinuclear 
factor [64] and anti-keratin antibodies [19, 65, 66] with the ability to recognize citrullinated 
peptides [67], and have since 2010 been included as one of the diagnostic criteria for the 
disease  [46]. Presence of ACPAs, measured by a diagnostic test based on reactivity against a 
synthetic cyclic citrullinated peptide (anti-CCP), can be detected up to 10 - 15 years before 
clinical onset of RA [68, 69], making them a useful diagnostic test for the detection of early 
disease. In addition, ACPA-positive RA is associated with a more severe disease 
course/radiological destruction [70-72], as well as major environmental and genetic risk 
factors for RA [smoking and HLA-DRB1 shared epitope (SE)] [32, 73], compared to ACPA-
negative disease subset. Due to the differences in genetic and environmental risk factors 
between ACPA-positive and ACPA-negative RA, different pathogenic pathways may 
underlie ACPA-positive and ACPA-negative disease subset [74]. Some of the most well 
characterized ACPAs in RA are citrullinated fibrinogen, vimentin, collagen and -enolase 
[74]. 
 11 
 
The RF antibodies, another diagnostic criteria for RA, were the first antibodies to be 
associated with the disease [46, 75]. This polyclonal antibody is primarily directed against the 
Fc region of immunoglobulin G (IgG), but can react with other antigens and is detectable also 
in other immunoglobulin subclasses (IgA, IgD, IgE, IgM) [76]. Even though RF is not 
specific for RA and can be found in a variety of other diseases [77], it is present in 
approximately 60 - 80% of RA patients (usually measured as IgM-RF) [76, 78, 79] and can 
be detected up to 5 - 15 years before disease onset [32, 80]. Moreover, most RA patients that 
are positive for ACPAs are also positive for RF [34], and the risk of RF-positive RA has been 
associated with both genetic and environmental risk factors (HLA-DRB1 SE and smoking) 
[32, 74, 81]. It has been suggested that RF by itself does not contribute to RA disease 
progression [82], as the association with joint destruction has been attributed to ACPA rather 
than RF [34, 82]. Nevertheless, RF is still used in classification criteria for RA, and a study 
from 2015 demonstrated an association between RF and increased disease activity in RA 
patients, in contrast to ACPAs [79]. 
 
SIMILARITIES BETWEEN PERIODONTITIS AND RA 
Periodontitis and RA are both chronic inflammatory diseases that can lead to permanent 
disability [83-85]. These two diseases share numerous features including tissue and bone 
destruction; production of inflammatory mediators including cytokines, prostaglandins and 
degradation enzymes (i.e. MMPs) and common risk factors such as smoking [86, 87]. The 
destruction of soft and hard tissue is a result of a large number of signal molecules released 
by inflammatory cells in the synovia/gingiva which contribute, directly or indirectly, to the 
degradation of tissue and bone [83-85]. Both diseases have similar cytokine profiles 
characterized by high levels of inflammatory mediators (such as PGE2, TNF-, IL-6 and IL-
1β) and degradation enzymes (e.g. MMP1, MMP9 and MMP13), and decreased levels of 
anti-inflammatory mediators (such as IL-10 and TGF-β) [85, 88-92]. In addition, a well-
established major risk factor for both periodontitis and RA is cigarette smoking. Higher 
frequency of bone loss, attachment loss and edentulism is exhibited in smokers, compared 
with non-smokers [93]. In RA, cigarette smoking has been reported to increases the risk of 
seropositive disease (both ACPA and RF) in genetically predisposed individuals, and has also 
demonstrated a dose-dependent effect regarding the risk of ACPA-positive disease [32, 81, 
94]. Moreover, a well-established genetic risk factor for RA, HLA-DRB1 SE alleles, has also 
been implicated as a risk factor for periodontitis [95-97]. Additionally, antibodies associated 
with RA (both ACPA and RF) have been detected in non-RA patients with periodontitis [87, 
98-100]. For example, individuals with periodontitis have higher serum ACPA-levels 
compared to healthy controls [99]. Furthermore, increased levels of citrullinated proteins 
have been reported in inflamed periodontal tissue [98, 101], and expression of ACPAs has 
been demonstrated in gingival crevicular fluid (GCF) and saliva of patients with RA [98, 
102]. Similarly, RF has been reported in gingiva, subgingival plaques and in serum of 
patients with periodontitis [87]. 
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BACTERIAL LINK BETWEEN PERIODONTITIS AND RA 
In 2004, a hypothesis of a possible pathogenic connection between periodontitis and RA was 
proposed, implicating the involvement of the periodontal pathogen P. gingivalis in the 
pathogenesis of RA, through the process of citrullination [24, 87]. Citrullination is an 
enzyme-mediated post-translational modification of the amino acid arginine in a protein into 
the non-standard amino acid citrulline (Figure 4) [74]. This process generates citrullinated 
proteins containing epitopes against which ACPAs can be raised [103].  Citrullination is 
driven by the enzyme peptidyl arginine deiminase (PAD), and the activity of this enzyme is 
dependent on high calcium concentrations [74]. To date, P. gingivalis is the only known 
pathogen with the ability to express a citrullinating PAD enzyme (P. gingivalis PAD, PPAD), 
equivalent to the PAD enzymes (PAD1 - 4 and PAD6) in mammals [87]. By the process of 
citrullination, PPAD could potentially initiate a local breakdown of tolerance to citrullinated 
proteins generated in gingiva, followed by epitope spreading to host-citrullinated proteins in 
the joint [24]. This mechanism (together with human PAD enzymes) could sustain the 
production of ACPAs, which can precede the development of RA, thereby implicating PPAD 
in the pathogenesis of RA [24]. In addition to the P. gingivalis link hypothesis, most recently 
Konig et al. suggested that another periodontal bacterium, A. actinomycetemcomitans could 
be associated with the RA related autoimmunity, due to its ability to trigger (trough 
leukotoxin A) an activation of citrullinating enzymes in host neutrophils [104]. Moreover, the 
same study also reported that, in patients with RA, the leukotoxic strain of A. 
actinomycetemcomitans was associated with both ACPA as well as RF antibodies [104]. 
Because these data are very recent, the association between RA and the leukotoxic strain of 
A. actinomycetemcomitans was not investigated in this thesis. 
 
PREVIOUSLY PUBLISHED STUDIES ON THE RELATIONSHIP 
BETWEEN PERIODONTITIS AND RA 
Incidence/prevalence and disease activity of RA in patients with periodontitis  
Previous studies, most of them with relatively low sample size, have proposed a correlation 
between RA and periodontitis [105-107], including increased incidence and prevalence of RA 
in patients with this periodontal disease [24, 108-112]. For example, in a study by Hashimoto 
et al. periodontitis correlated with the incidence of RA in 72 individuals with arthralgia [24]. 
Furthermore, in a study including 32 American patients with new-onset RA, high prevalence 
of periodontitis was reported at disease onset [108]. Regarding studies with large number of 
patients, in one of the largest studies to date (13 779 Taiwanese patients with newly 
diagnosed RA and 137 790 controls), a weak association (OR = 1.16, 95% CI: 1.12 – 1.20) 
was reported between periodontitis and incident RA based on administrative data from the 
National Health Insurance Program [109]. Importantly however, authors concluded that this 
weak association was further limited due to lack of information about the subjects smoking 
habits, a well-known risk factor for RA and periodontitis [109]. Presence of periodontitis has 
also been associated with RA disease activity [105, 111, 113-115]. In addition, a dose- 
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response pattern between periodontitis severity and RA disease activity has been reported. 
For example, higher RA disease activity, as indicated by higher DAS28 score, has been 
described in RA patients with periodontitis [111, 113, 114, 116]. In addition, subjects with 
severe periodontitis demonstrated highest DAS28 scores compared to moderate or 
periodontitis-free individuals [111]. Furthermore, in an Australian population (including 65 
RA cases and 65 controls), increased periodontal bone loss and deeper pockets were 
associated with indicators of RA disease activity, such as higher number of swollen joints, 
and levels of CRP and ESR in patients with RA [117]. Conversely, there are also studies 
reporting no association between levels of ESR or CRP and periodontitis [106, 118]. A meta-
analysis performed in 2013 by Kaur et al. reported no statistical difference in ESR titers, and 
only low level of evidence for elevated CRP and the association with periodontitis in RA 
subjects [106]. 
 
Figure 4.
The process of citrullination of proteins, driven by the calcium dependent petidyl arginine
deiminase (PAD) enzyme. Deimination of peptidylarginine to peptidylcitrulline is a post-translation-
al process, also known as citrullination. The enzymatic conversion results in the loss of one
positive charge for every arginine residue converted to a neutral citrulline. This causes changes in
intra- and intermolecular interactions, which could lead to altered protein folding, enhanced
degradation by proteases, and exposure of cryptic epitopes. RA specific antibodies (ACPAs) can
recognise and bind to citrullinated proteins. The production of citrullinated proteins can thereby
contribute to the autoimmune reponse in RA.
ACPA, anti-citrullinated protein antibody.
Adapted and reproduced from Klareskog et al 2008 [74], with premission fromAnnual Reviews.
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Prevalence/severity of periodontitis in patient with RA 
In accordance with reports that patients with periodontitis have increased risk for RA/severe 
RA, as discussed previously, it has also been published that patients with RA have increased 
risk of periodontitis/severe form of periodontitis. Numerous studies have shown that patients 
with RA have substantially increased frequency of periodontitis/severe periodontitis as 
compared to healthy individuals [40, 87, 108, 111, 113-115, 117, 119-127]. For example, in 
an American study (including 103 RA cases and 4358 controls) patients with RA were more 
likely to be edentulous and have periodontitis compared to controls [124]. In a Finnish 
population, poorer periodontal parameters were reported in patients with chronic active RA as 
well as in a population with early untreated RA, when compared to non-RA controls [127]. 
Furthermore, in an Indian population, the odds of periodontitis were 4.28 (95% CI: 2.35 – 
7.38, p < 0.001) times higher in non-smoking DMARD-naive RA participants as compared to 
healthy controls (prevalence 64.8% versus 28%, p < 0.001) [113]. Additionally, in the same 
population, periodontitis was associated with higher titers of ACPA among RA cases [113]. 
Similarly, in studies comparing the periodontal health of patients with RA to that of non-
inflammatory arthritis (osteoarthritis), it was demonstrated that periodontitis is more common 
in both RA and ACPA-positive RA subjects compared to patients with osteoarthritis [114, 
116, 128, 129]. Moreover, a review article by Kaur et al. indicated that more severe 
periodontitis including greater CAL and increased tooth loss is associated with RA, although 
the authors concluded that larger population-based studies were needed to confirm this link 
[106]. 
Studies reporting no association between periodontitis and RA 
In contrast to the studies reporting an association between periodontitis and RA, there are also 
reports, including both large population-based [130, 131] and clinical studies [118, 132-138], 
demonstrating no differences in prevalence of periodontitis between RA patients and healthy 
controls [130, 131, 133, 134]. In addition, even less severe periodontal tissue destruction in 
subjects with RA has been described [135, 137, 138]. For instance, in a longitudinal study 
conducted over a time period of 20 years (9702 patients, 138 with established RA and 433 
with incident RA) subjects with periodontal disease displayed numerically higher 
prevalent/incident RA than subjects without periodontitis, although most ORs were non-
statistically significant [131]. Furthermore, the largest prospective study to date, conducted 
among 81 132 American women including 292 with incident RA, reported no association 
between severe periodontitis (as estimated by history of periodontal surgery and/or tooth loss) 
and risk of RA [130]. Additionally, one of the earliest clinical case-control studies, 
comparing periodontal parameters among Swedish subjects with RA (n = 161) and matched 
controls (n = 204), showed even less frequent severe periodontal breakdown in patients with 
RA [135]. 
The conflicting reports on the relationship between periodontitis and RA, described above, 
may depend on ethnic differences between study populations and/or substantial differences in 
disease classification criteria for periodontitis. In 2013, Linden et al. concluded that studies 
do not provide support for a link between periodontitis and RA since very few studies meet a 
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stringent threshold for periodontitis [139]. Although most of the previous studies today 
suggest that an association between periodontitis and RA exists [108-117, 120-124, 128], 
even more recent review articles conclude that studies with sufficient sample sizes are still 
needed to ascertain the temporal relationship between these two diseases [107, 140]. 
Moreover, in a recently published review by Chapple et al. the authors state that even though 
patients with RA seem to have an increased prevalence of periodontitis, they deemed the 
certainty of this association as low [141].  
Effects of periodontal treatment on RA 
Results from previous clinical studies indicate that non-surgical periodontal treatment may 
have beneficial effects on RA disease severity [105, 142-144]. Scaling and root planning in 
RA patients with chronic periodontitis have resulted in significant reduction of RA disease 
activity and serum levels of TNF- [143-151], in some cases regardless of RA medications 
[148, 152]. Furthermore, periodontal treatment has been reported to significantly reduce 
ACPA levels in non-RA patients with periodontitis [99], however, these results have not yet 
been demonstrated in subjects with RA [106, 143, 144]. Likewise, no statistical difference in 
RF-levels has been demonstrated following non-surgical periodontal therapy [143, 150], 
indicating no effect of periodontal therapy on serological markers for RA. In recently 
published review articles it was highlighted that there is a need for additional randomized 
controls trials and large-scale longitudinal intervention studies investigating the effect of 
periodontal therapy on RA disease activity [105, 142]. 
Effects of RA medication on periodontitis 
Studies indicate that treatment of RA with biological agents, such as anti-TNF- and IL-6 
inhibitors, may have beneficial effect on periodontitis [88]. Anti-TNF- therapy 
(adalimumab, infliximab) can significantly decrease clinical parameters of periodontitis 
severity (BOP, gingival index, PPD and CAL) without additional periodontal treatment [153-
156]. Attachment loss significantly decreased in patients evaluated before and after 
infliximab-therapy [153]. The decrease in the severity of periodontitis might be explained by 
the fact that anti-TNF- therapy also reduces the levels of inflammatory cytokines (IL-1β, IL-
6, IL8, MCP-1 and TNF-) in serum and GCF samples of patients with RA [154, 155, 157]. 
Furthermore, one study reported similar results after IL-6 receptor (IL-6R) inhibition therapy  
showing reduction in gingival index, BOP, PPD, CAL, serum IL-6 and MMP3 in RA 
subjects, without additional periodontal therapy [158]. However, the positive effect of 
biological agents on the periodontal condition has not been successfully replicated in all 
studies [148]. In patients with active RA for example, PPD was not affected after 6 weeks of 
anti-TNF- therapy, even though the gingival inflammation (BOP) was reduced [156]. 
Moreover, in 40 patients with moderate/severe RA, anti-TNF- therapy (without any 
additional periodontal treatment) had no effect on periodontitis [148].   
Previous studies investigating the effect of periodontal treatment on RA disease activity and 
vice versa the effect of RA medication on periodontitis include low sample size and relatively 
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short observation time (up to 6 months follow-up) [88, 105, 153]. Thus, the effect of 
periodontal therapy on RA disease activity [105, 142] as well as the therapeutic efficiency of 
RA biological therapy (inhibition of pro-inflammatory cytokines) on periodontitis require 
more extensive studies including larger cohorts in order to better assess their efficacy [88]. 
Experimental periodontitis and arthritis – results from animal studies 
In addition to human studies, animal studies have also been performed to investigate the 
relationship between periodontitis and arthritis. Chronic oral infections with periodontal 
pathogens have been demonstrated to affect arthritis development in animal models [105, 
159-161]. For example, infection with P. gingivalis aggravated experimental arthritis in mice 
and rats, as indicated by more rapid onset of disease, increased bone loss/cartilage destruction 
and paw swelling [84, 162-166]. Moreover, rats with experimental arthritis have shown 
increased periodontal bone loss and tooth mobility, without being induced with experimental 
periodontitis [165, 167]. 
P. gingivalis is currently the most common oral bacterium used in animal models 
investigating the effect of oral pathogen infection on arthritis development [84, 159, 161-
164]. The ability of P. gingivalis to exacerbate arthritis seems to be dependent on PPAD 
expression, as the extent of experimental arthritis is reduced in animals infected with a 
PPAD-deficient strain before arthritis-induction [162, 163]. Moreover, PPAD may be 
associated with the serum levels of ACPAs in mice [162, 163]. Gully et al. demonstrated a 
tendency towards higher ACPA serum levels in animals that were infected with wild-type P. 
gingivalis, as compared to a PAD-deficient P. gingivalis strain [162]. 
There are, however, animal studies that do not report an increase in arthritis severity by 
periodontitis co-induction [159, 163]. Mice infected with P. gingivalis or A. 
actinomycetemcomitans showed no differences in arthritis severity parameters [159]. 
Furthermore, infection with Prevotella intermedia and heat-killed P. gingivalis failed to cause 
aggravation of experimental arthritis in mice [163]. A possible explanation for this lack of effect 
on arthritis severity may be that the systemic effect of certain strains of periodontal pathogens or 
types of experimental periodontitis is lower than that of experimental arthritis, thus insufficient 
for modulating arthritis severity [159, 163]. Another explanation may be that live bacteria, 
associated with some active bacterial component, are needed in order to have a systemic effect on 
the host and trigger an autoimmune response [163]. 
Studies investigating the P. gingivalis bacterial link hypothesis 
In support of the P. gingivalis-hypothesis linking periodontal pathogens to the pathogenesis 
of RA, antibodies against P. gingivalis as well as P. gingivalis DNA has been detected in 
serum, synovial fluid and synovial tissue of patients with RA [168-171]. Anti-P. gingivalis 
antibodies have also been associated with the presence of ACPAs [114, 172, 173]. In 
addition, it has been demonstrated that PPAD is capable of citrullinating RA-specific antigens 
such as human fibrinogen and -enolase, the two major citrullinated autoantigens in RA [24, 
174]. Because antibodies to human citrullinated -enolase peptide 1 (CEP-1) can cross-react 
with the P. gingivalis citrullinated version of the same peptide, a bacterial infection could 
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potentially be involved in breaking immune tolerance and leading to autoantibody generation 
in susceptible individuals [175]. Moreover, PPAD itself could be the citrullinated antigen that 
breaks the immune tolerance, as previous data has showed that PPAD polypeptide chain can 
undergo auto-citrullination [160, 176, 177]. Interestingly, antibody response against 
citrullinated PPAD is elevated in sera from patients with RA and ACPA-positive RA, in 
contrast to PPADs uncitrullinated form [176, 177]. In animal studies, P. gingivalis ability to 
aggravate experimental arthritis has been attributed to PPAD [162]. Mice infected with 
PPAD deficient strain of P. gingivalis demonstrated significantly reduced extent of arthritis 
[162]. However, the results from studies investigating the P. gingivalis bacterial link between 
periodontitis and RA are inconsistent. Some reports demonstrate no association between the 
presence of P. gingivalis and RA, and no correlation between anti-P. gingivalis antibodies 
and RA severity/ACPA status in patients with RA [112, 168, 178-180].  
Summary of previously published studies 
Periodontitis and RA share several features including pathogenic processes and 
environmental risk factors such as smoking [88, 106]. Epidemiological studies suggest that an 
association exists based on increased incidence of periodontitis in patient with RA and a 
dose-response pattern between periodontitis severity and RA disease activity [105]. However, 
available data is controversial, possibly due to the heterogeneity in the definition of 
periodontitis [139]. Although periodontal pathogens (such as P. gingivalis) might be a link in 
the association between periodontitis and RA, not all studies show this association and there 
is a lack of evidence for a direct role in the temporal relationship [105, 179, 180]. The results 
of intervention studies, indicating that non-surgical periodontal treatment can improve RA 
disease activity in individuals with comorbid disease are still preliminary due to small 
number of subjects and short follow-up time [105, 142, 145, 149, 181]. Larger studies with 
well-defined populations, well-defined clinical outcomes and longer follow-up time are 
required to explore the biochemical processes, effect of therapy as well as the clinical 
relationship between these two diseases [68, 88, 106, 140, 181]. A causative role of 
periodontitis or periodontal bacteria in RA pathogenesis still remains speculative [105, 140]. 
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AIMS OF THE THESIS 
 
 
 
 
General aim 
The general aim of this thesis was to study the relationship between periodontitis and RA. 
 
Specific aims 
Study I 
The aim of Study I was to investigate the prevalence of periodontitis in patients with RA, with 
special focus on seropositivity, both ACPA and RF, in the Swedish population-based 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) case-control study, by linking 
EIRA with the National Dental Health Registry (DHR). 
 
Study II 
Study II aimed to explore the effects of pre-existing periodontitis, induced by periodontal 
pathogens in combination with ligatures, on the development and the immune/inflammatory 
response of experimental arthritis. 
 
Study III 
In Study III the objective was to investigate the presence of citrullinated proteins and the 
protein expression of the citrullinating enzymes PAD2 and PAD4, in relation to P. gingivalis 
in gingival biopsies from patients with and without periodontitis. 
 
Study IV 
Study IV aimed to investigate the severity of periodontitis in patients with established RA, in 
relation to antibody status (ACPA and RF), medication, clinical and immunological 
parameters associated with RA, and the presence of P. gingivalis. 
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MATERIALS AND METHODS 
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he following chapter will present an overview of the methods used to obtain the results 
in Studies I - IV, included in this thesis. A brief information about the study design, 
recruitment of participants and experimental techniques will be outlined. For more detailed 
information about the participants, protocols, chemicals and substances used, please refer to 
the Materials and Methods sections of Studies I - IV. 
 
ETHICAL CONSIDERATIONS 
All of the studies in this thesis followed the ethical principles for medical research as stated in 
the Declaration of Helsinki, and were conducted in accordance with current legislation in 
Sweden. Ethical permits were obtained from the Regional Ethical Review Board in 
Stockholm (Studies I, III and IV) or the Stockholm North Animal Ethics Committee (Study 
II), before initiation of each study. In studies involving human subjects (Studies I, III and IV) 
a written informed consent for participation was obtained from all subjects prior to inclusion. 
 
HUMAN STUDY POPULATIONS (Studies I, III and IV)  
The Studies I, III and IV contain data, samples and gingival biopsies from human subjects. In 
the first study we investigated the prevalence of periodontitis in patients with RA and 
matched healthy controls in relation to autoantibody status, by linking data from two Swedish 
registries. Study III investigated the potential for citrullination (possibly contributing to 
autoimmunity) in gingival tissue from patients with periodontitis and healthy controls, by 
studying the expression of citrullinated proteins and citrullinating enzymes in gingival 
biopsies. A clinical evaluation of periodontitis severity in RA patients, in relation to 
autoantibody status, was performed in Study IV.  A schematic illustration of the study designs 
of the above mentioned studies are demonstrated in Figure 5. 
EIRA and DHR registries (Study I) 
In Study I the prevalence of periodontitis was investigated in 2740 subjects with RA and 3942 
matched healthy control included in the Swedish population-based case-control study EIRA. 
The EIRA registry was initiated in May 1996 and contains the participants’ genetic, 
environmental and serological data (ACPA and RF status). The participants included in Study 
I were enrolled until October 2009. At the time of admission into the EIRA registry, all 
patients with RA were newly diagnosed by rheumatologists according to the 1987 American 
College of Rheumatology (ACR) Criteria for RA. The healthy controls were recruited from 
the Swedish national population registry, and were matched to RA cases based on age, gender 
and residential area.  
T 
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Information about the prevalence of periodontal diagnoses among the participants was 
obtained by linking the EIRA registry to the Swedish DHR through the participants’ social 
security numbers. The DHR contains information about dental diagnostic- and treatment 
codes for all Swedish citizens over the age of 20 who have visited the dentist at least one 
since the initiation of the registry (July 2008). All diagnoses in the DHR have been 
registered by a dentist or a dental hygienist. In Study I we focused our attention on specific 
periodontal diagnostic codes including: increased risk of periodontitis (2041), increased 
risk of peri-implantitis (2051), gingivitis (3041), periodontitis (3043) and peri-implantitis 
(3044). We also analyzed the prevalence of periodontal treatment codes registered in 
combination with the diagnostic codes for periodontitis (3043) and increased risk of 
periodontitis (2041). The investigated treatment codes were: minor non-surgical treatment 
of periodontal disease, major non-surgical treatment of periodontal disease including 
several deep pockets and/or furcation involvement, as well as the codes for surgical 
treatment. We identified 86% of the EIRA study population, both RA cases and controls 
who had visited the dentist after July 2008, in the DHR. There were no significant 
differences between the identified RA cases and controls regarding gender, age or 
ACPA/RF antibody status. 
Dental records (Study I) 
At the time of Study I, the DHR was a new and not yet validated registry. Therefore, in 
addition to the linkage analysis, we decided to validate the periodontal diagnostic codes 
and confirm the diagnoses by using information from the patients dental records. At the 
time of enrollment into EIRA, the RA cases and controls had completed a questionnaire 
covering a broad range of topics, including one question related to periodontal disease. 
The subjects answering “Yes” to the periodontitis-related question were asked to 
participate in the validation of the DHR by giving their permission to examine their dental 
records. The request was sent to 151 RA subjects and 155 controls, of which 100 subjects 
in total (50 RA cases and 50 controls) gave their informed consent to participate. 
Periodontal diagnosis was based on oral radiographs and all other information in the dental 
records, which were reviewed by two independent dentists. Criteria from the International 
Consensus Report on Chronic Periodontitis [182] were used to define and diagnose 
periodontitis. 
Gingival biopsies (Study III) 
In Study III, gingival biopsies were collected from patients with and without periodontitis 
(15 in each group) in order to study the expression of citrullinated proteins and human 
citrullinating enzymes (PAD2 and PAD4), in relation to P. gingivalis, in the inflamed and 
healthy gingival tissues. The mean age of the participants with and without periodontitis 
was 49 and 40 years, respectively (Figure 5). All patients in the periodontitis group 
demonstrated radiographic bone loss and probing pocket depth of ≥5 mm at the site of the 
collected biopsy. Patients included in the control group without periodontitis had no signs 
 25 
 
of radiographic bone loss and probing pocket depth ≤3 mm. All participants were 
systemically healthy and did not take anti-inflammatory drugs. 
Clinical assessment and samples collection in patients with RA (Study IV) 
A clinical evaluation of the periodontal health of subjects with RA was conducted in Study 
IV. The population consisted of 40 patients, aged 29 - 80, fulfilling the 2010 ACR criteria 
for RA (Figure 5). The gender distribution, including a majority of female participants, 
was representative for RA given that this disease is known to be more common in women.  
All participants underwent a full-mouth dental and periodontal examination, performed by 
the same dentist. Patients were divided into two groups based on their periodontal 
diagnosis (no/mild of moderate/severe periodontitis) (Figure 5). The examining dentist did 
not have information about the participant’s periodontal or rheumatological status 
beforehand. Periodontitis in Study IV was diagnosed following the standardized clinical 
definition of periodontitis intended for use in population-based studies [16].   
Various parameters related to RA disease activity were analyzed in patients with no/mild 
and moderate/severe periodontitis, including the self-assessed health (HAQ) score, the 
DAS28 score, autoantibody status (ACPA and RF), CRP levels as well as a number of 
inflammatory mediators. The presence of subgingival P. gingivalis was investigated in 
relation to periodontal diagnosis and ACPA antibody status.  
Samples were collected during the dental examination in order to investigate the presence 
of RA related autoantibodies, CRP levels, the presence of P. gingivalis and the expression 
of inflammatory mediators. The collected samples included blood, saliva, GCF and 
subgingival plaque, which were all stored at -80°C until analysis. For information about 
the sampling procedure, handling and preparation of different samples the reader is 
referred to the Methods section in the manuscript (Study IV). 
 
ANIMAL STUDY (Study II) 
To investigate the effects of pre-existing periodontitis on arthritis, an experimental animal 
model was used in order to achieve the immune systems complex interactions within the 
body. An in vivo model was chosen because the immune systems complexity cannot be 
reproduced in vitro in a cell culture environment, and there were no in-silico models that 
could replace the in vivo model. 
Animals 
Study II included 25 inbred adult male Dark Agouti (DA) rats, weighting between 165 and 
220 g. This rat stain has previously been used in arthritis research as it is highly 
susceptible to both acute and chronic types of arthritis. All animals were bred and housed 
under pathogen free conditions in individually ventilated cages at the Medical 
Inflammation Research facility, Karolinska Institutet, and received water and food at 
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libitum. The duration of Study II was set to 15 weeks to include both active and chronic 
arthritis. At the beginning of the study the animals were randomly divided into one of the 
following three groups: (1) a group consisting of both experimental periodontitis and 
arthritis (PA, n = 9), (2) a group with only experimental arthritis (A, n = 12) and (3) a 
small control group (Healthy, n = 4) used mainly to monitor the normal physiological 
changes in the animals over time (Figure 6). 
Experimental periodontitis and arthritis 
Experimental periodontitis was induced during a course of 8 weeks, prior to arthritis 
induction, to facilitate a severe chronic periodontal disease. The animals were anesthetized 
using isoflurane and silk ligatures that promote bacterial adhesion were placed and knotted 
at the cervical part of the two upper second molars of each rat in the PA group, to induce 
the development of experimental periodontitis. The ligatures were checked every 10 days 
and replaced if loosened. To further facilitate the progression of periodontitis and to ensure 
the presence of the periodontal pathogen P. gingivalis (potentially implicated in the 
association between periodontitis and RA), weekly bacterial swabs were administered 
containing the pathogens P. gingivalis and F. nucleatum (known to promote the 
colonization of P. gingivalis). The rats without experimental periodontitis (the A and the 
healthy control group) received swabs with only the vehicle (4% Gantrez) that was used to 
reconstitute the bacteria in the PA group. The presence and progression of periodontitis 
was clinically monitored in all animals every 10 days throughout the course of the study, 
and assessed radiographically at endpoint (Figure 6).  
After 8 weeks, a well-established model of arthritis, the pristane-induced arthritis (PIA), 
was used to induce the disease in both the PA and the A group (Figure 6). The PIA model 
closely mimics human RA by triggering a chronic relapsing form of arthritis that 
additionally fulfills many criteria for RA including presence of RF, symmetrical 
involvement of peripheral joints as well as cartilage and bone destruction. PIA was 
administered by a single intradermal pristane-injection at the dorsal side of the rats’ tail, 
and clinical manifestations of arthritis were visible 2 - 3 weeks post injection. The 
development and severity of arthritis was monitored continuously by two independent 
examiners, using a previously describes visual scoring system [183] which assesses the 
inflammation in wrists, ankles, knuckles and toes. Weight changes were also recorded as 
an objective measure of arthritis disease activity.  
Sample collection in the animal study 
Every 10 days blood samples were collected from the tail of each rat, during anesthesia 
with isoflurane, to monitor the levels of acute phase proteins such as -1-acid glycoprotein 
(-1-AGP). At the end of the 15 week long experiment additional blood samples were 
collected by cardiac puncture to investigate the presence of antibodies against arginine 
gingipain B (RgpB) which is a virulence factor of P. gingivalis essential for PPAD 
citrullination, antibodies against citrullinated peptides, as well as the levels of 
inflammatory markers and cytokines. 
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The ligatures were recovered at the end of the study (week 15) to confirm the presence of 
P. gingivalis and F. nucleatum at the infected sites. One ligature per rat was transferred 
into FAB-medium and transported to the laboratory to culture the bacterial flora on 
anaerobic plates. The other ligature was snap-frozen in liquid nitrogen and transferred to  
-80°C, pending quantitative polymerase chain reaction (qPCR) analysis to detect specific 
bacterial DNA.  
To assess the alveolar bone loss at endpoint (week 15), the heads of the animals were 
collected in 4% formaldehyde and stored at 4°C, for radiographic analysis. The front and 
hind paws were also collected and stored in the same way, to radiographically illustrate the 
bone loss and arthritis inflammatory changes in the rats. To detect the presence of bacterial 
Figure 6.
A schematic illustration and timeline of the experimental protocol. Briefly, in the PA group, the
experimental periodontitis was induced by tying silk ligatures around the upper second molars of
DA rats and administering oral bacterial swabs (with P. gingivalis and F. nucleatum recostituted in
4% Gantrez medium). The periodontal status and tooth mobility were asssesed in all animals (PA,
A and Heathy) every 10 days. In the PA group, additional bacterial swabs were also administered
in-between the times for periodontal examination. Rats in the A and the Healthy control groups
received swabs with only 4% Gantrez medium. At week 8, experimental arthritis (PIA) was induced
in the PA and the A groups and arthritic changes were monitored in all animals until the end of the
experiment (week 15).
PA, animals with experimental periodontitis and induced arthritis; A, arthritis induced animals with-
out periodontitis; Healthy, animals without experimental periodontitis or arthritis, DA, Dark Agouti;
PIA: pristane-induced arthritis.
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genomic DNA (gDNA) in the connective tissue and capsule of the joints, one paw per rat 
was frozen in liquid nitrogen and stored at -80°C for qPCR analysis. For details about the 
radiographic examination and the qPCR analysis the reader is referred to the Methods 
section of Study II. 
 
ANALYSIS OF SAMPLES (Studies II, III and IV) 
Quantitative polymerase chain reaction (qPCR) (Studies II and IV) 
The presence of P. gingivalis in Studies II and IV was detected by qPCR analysis. First, 
gDNA containing the organisms genetic data, was isolated from the ligatures and 
subgingival plaque samples by using a QIAamp DNA Mini Kit (Qiagen, USA). During 
gDNA extraction the ligatures and bacterial plaque samples were resuspended in tissue 
assay buffer and lysed with proteinase K at 56°C, followed by washing steps with ethanol 
containing assay buffers as instructed by the manufacturer. The quantification and quality 
of the extracted gDNA was assessed spectrophotometrically with NanoVue 
spectrophotometer (GE Healthcare Bio-Science, Sweden) (Study II) or Quibit 2.0 
fluorometer (Invitrogen, Life Technologies, USA) (Study IV). 
The isolated gDNA was used in qPCR analysis to investigate the presence of bacteria in 
ligatures and joints from DA rats (Study II) and subgingival plaque samples from patients 
with RA (Study IV). In Study II, 40 ng of the target gDNA was assayed together with 
TaqMan Universal PCR Master Mix (2x) (Applied Biosystems, USA) and the specific 
bacterial primers and probe (Cybergene AB, Sweden), in a total reaction volume of 20 μl. 
In Study IV, the reaction volume of 20 μl comprised of 5 ng of template gDNA, TaqMan 
Universal PCR Master Mix (1x) together with the specific primers and probe (Eurofins 
Genomics, Ebersberg, Germany). The primers and probes used in these studies, targeting 
P. gingivalis and the universal 16S ribosomal RNA gene (16S), are described in detail in 
the manuscripts of Study II and IV. In both studies the 7500 Fast Real-Time qPCR System 
(Applied Biosystems, Foster City, CA, USA) was used and programmed as follows: initial 
incubation at 50°C for 2 min, a 10 min denaturation at 95°C followed by 40 PCR cycles of 
annealing at 95°C for 15 s and extension at 60°C for 1 min. 
Analysis of CRP, -1-AGP, RbpB, citrullinated/uncitrullinated PPAD 
peptides and inflammatory mediators (Studies II and IV) 
To detect the levels of CRP and -1-AGP, and the antibody levels against RgpB and 
citrullinated/uncitrullinated PPAD peptides (CPP3/RPP3), an enzyme-linked 
immunosorbent assay (ELISA) approach was applied. In Study II, plasma levels of CRP 
and -1-AGP were detected by using prefabricated ELISA kits according to manufacturer 
instructions (Sigma-Aldrich, USA and Life Diagnostics Inc., USA, respectively). The 
samples, diluted 1:40 000, were incubated with the target specific antibodies (biotinylated 
rat CRP or anti-rat -1-AGP) for 1 h or 45 min, respectively. Next the substrate-antibody 
complex solution was incubated with the enzyme horseradish peroxidase (HRP) conjugate 
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secondary antibody and finally the tetramethylbenzidine (TMB) reagent, which together 
form a colored product that can be detected spectrophotometrically. The absorbance of this 
colored substrate-antibody product was measured at 450 nm, and the plasma levels of CRP 
and -1-AGP were calculated using mean absorbance from the standard curve. In Study 
IV, the CRP levels were measured in a similar matter by a commercially available ELISA 
kit (USCN Life Science, Wuhan, China). The saliva and GCF samples in Study IV were 
diluted 1:3 and 1:2, respectively, before being incubated with the CRP antibodies for 2 h, 
followed by incubation with HRP-conjugate secondary antibody and subsequently 
detected with TMB. The levels of antibodies against RgpB and citrullinated/uncitrullinated 
PPAD peptides investigated in Study II, were measured using an in-house ELISA [184]. 
Here the plasma samples were diluted 1:50 and 1:2, respectively, and incubated overnight 
in plates (MaxiSorp, Nunc) coated with RgpB (3.4 μg/ml) or CPP3/RPP3 protein (10 
μg/ml). After a washing step with PBS-Tween (0.05%) the plates were incubated for 1 h 
with HRP-conjugated goat anti-rat IgG (Jackson Immuno Research Inc, USA) and the 
absorbance was measured at 450 nm.  
Concentrations of cytokines and inflammatory mediators were investigated using the Bio-
Plex 200 system and Bio-Plex immunoassay; specifically the Bio-Plex Pro™ Rat 
Cytokine 24-Plex and the Bio-Plex Pro™ Human Inflammation Panel 1, 37-Plex (Bio-
Rad, Sweden), according to the manufacturer protocols. Detailed information about the 
investigated inflammatory mediators, including sensitivity levels, is provided in the 
Methods section of Study II and IV.   
Immunohistological staining (Study III) 
Immunohistochemical stainings were performed in Study III to detect the presence of 
citrullinated proteins and citrullinating enzymes (PAD2 and PAD4) in inflamed and 
healthy gingival tissues. The collected gingival biopsies were embedded in paraffin and 
sectioned (4 μm thickness). Sections of each biopsy were deparaffinised using xylene, 
rehydrated and stained with primary antibodies directed against citrullinated proteins 
(F95), PAD2 and PAD4 (Cosmo Bio, ROI002, Tokyo, Japan and Abcam, AB128086, 
Cambridge, UK, respectively) or against P. gingivalis using monoclonal antibodies 
produced by hybridoma HB-9968 (from ATCC). Isotype-matched control antibodies, 
mouse myeloma IgM (for F95), rabbit immunoglobulin fraction (for PAD2), mouse IgG1 
(for PAD4) and IgG2b (for P. gingivalis), were used to stain corresponding negative 
control sections. Next, the sections were incubated with biotinylated secondary antibodies, 
goat anti-mouse IgM or goat anti-rabbit IgG (Vector Laboratories, USA), and the avidin-
biotin complex (ABC-Elite solution) was used to enable the binding between the 
secondary antibody and peroxidase in the next step. The diaminobenzidine (DAB) 
substrate was added to the sections to obtain a brown colored product, visualizing the 
antigen localization. All sections were counterstained using Mayer´s hematoxylin to stain 
the cell nuclei blue and provide contrast, making visualization easier. To illustrate T-cell 
infiltration, sections of the gingival tissues were also stained with antibodies against the 
cluster of differentiation molecule CD3 (DAKO, A0452, Glostrup, Denmark). A visual 
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scoring system, with a 4 point scale (ranging between 0 – 3), was used to assess the grade 
of inflammation and the degree of positively stained cells in the gingival tissues. For 
details about the protocol and the scoring system please see under the Materials and 
Methods section in Study III. 
 
STATISTICAL ANALYSES (Studies I - IV) 
The Chi-square test or Fisher´s exact test was applied in Studies I, III and IV, to analyze 
the differences in dichotomous variables (e.g. nominal variables with only two categories 
such as gender, number of positively stained gingival samples or patients positive for P. 
gingivalis) between the groups.  The Mann-Whitney U test and the two sample t-test were 
used when analyzing ordinal and continuous variables, such as differences in histological 
scoring, alveolar bone level or levels of inflammatory mediators etc (applied in Studies II, 
III and IV). A logistic regression analysis was performed in Studies I and IV to analyze the 
associations between RA related autoantibodies (ACPA/RF) and the prevalence and 
severity of periodontitis or presence of periodontal bacteria. The estimated odds ratios 
with 95% confidence interval were adjusted for residential area (Study I), gender, age and 
smoking habits (Studies I and IV). In all studies, p value of less than 0.05 was considered 
statistically significant. 
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n the following section the results from studies included in this thesis will be highlighted 
and discussed in relation to previous literature. The full-length manuscripts of all included 
studies are available in the appendix. Studies I and II have been published in open access 
peer-reviewed journals and are reproduced in their published form. Studies III and IV are in 
manuscript form. 
 
STUDY I 
Prevalence of periodontal diagnostic codes in patients with RA and controls 
The prevalence of periodontal disease, determined by periodontal diagnostic codes registered 
in the DHR by dentist and dental hygienists, was investigated in patients with RA and 
matched healthy controls included in the EIRA study. By performing a linkage analysis 
between the two Swedish registries, DHR and EIRA, we were able to investigate the 
prevalence of periodontal diagnoses in 2343 patients with RA and 3386 matched healthy 
controls. These subjects, representing 86% of the entire EIRA cohort (n = 6682), had visited 
the dentist at least once since the initiation of the DHR in 2008. Our results showed no 
differences in prevalence of gingivitis, periodontitis, peri-implantitis or increased risk of 
periodontitis/peri-implantitis between RA patients and controls (Table 2).  
 
Table 2. Prevalence of periodontal diagnostic codes in RA cases and controls 
Diagnosis RA cases 
 
Controls 
 
p value
†
 
Gingivitis  784 (33)  1193 (35)  NS 
Increased risk of periodontitis  597 (25)  932 (28)  NS 
Increased risk of peri-implantitis    17 (0.7)  20 (0.6)   NS 
Periodontitis  762 (33)  1091 (32)  NS 
Peri-implantitis  109 (4.7)  140 (4.1)  NS 
Results are presented as number (%). RA, rheumatoid arthritis; NS, not significant. 
†
Statistical differences in prevalence of periodontal diagnostic codes between RA cases and 
controls. p value < 0.05 was considered statistically significant.  
 
Our findings are in agreement with several other reports, showing no significant association 
between RA and prevalence/severity of periodontitis [118, 130, 132-137, 185]. For example 
in both an Indonesian (75 RA; 75 controls) and a Japanese population (80 RA; 38 controls), 
no differences in prevalence of periodontitis were reported between patients with established 
RA and healthy non-RA controls [133, 134]. Moreover, in the largest prospective study to 
date, including 81 132 female nurses of whom 292 developed RA, no association was found 
between incident RA and periodontal surgery and/or tooth loss [130]. On the contrary, several 
other studies have reported more prevalent and severe periodontitis in patients with RA, as 
compared to healthy controls [108-110, 112, 113, 115, 117, 119-122, 124, 125, 142]. For 
example, a weak but significant association was found between periodontitis and RA (OR = 
I 
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1.17; 95% CI: 1.15 – 1.19, p < 0.001) in the largest registry study conducted to date, 
comprising of 1 025 340 Korean patients with different diseases (57 024 with RA out of 
which 46% had periodontitis) [112]. Similar ORs (OR = 1.16; 95% CI: 1.12 – 1.20) were 
reported in the second largest study, a Taiwanese linkage study including 13 779 patients 
with newly diagnosed RA in a total of 151 569 participants [109]. However, importantly, in 
these two large population based studies the authors were not able to adjust the analysis for 
smoking, the major confounding factor for periodontitis [112]. The inconsistent reports on the 
association between RA and periodontitis could be due to several factors such as ethnic 
differences between cohorts or differences in definition of periodontitis. In 2013 a review by 
Linden et al. concluded that there was a substantial heterogeneity of periodontitis definitions 
in previous studies and that very few reports met a stringent threshold for the disease [139]. 
The authors further stated that the previously conducted studies did not support a link 
between RA and periodontitis [139]. Although the definition of periodontitis still varies 
between different studies, recent systematic reviews and meta-analyses conclude that there is 
support for an association between RA and periodontitis [140, 186], and that the risk of 
periodontitis is increased in subjects with RA (relative risk = 1.13; 95% CI: 1.04 – 1.23, p = 
0.006) [140].   
Prevalence of non-surgical and surgical periodontal treatment in patients with 
RA and controls 
In an effort to assess the severity of periodontitis in RA cases and controls, the prevalence of 
different non-surgical and surgical treatment codes were also investigated. The prevalence of 
the non-surgical periodontal treatment codes, recorded in combination with the diagnostic 
code for “periodontitis”, showed no differences between RA patients and controls. The code 
for minor non-surgical treatment was prevalent in 59% of the RA cases and in 61% of the 
controls, whereas major non-surgical treatment was reported in 58% and 56% of the patients, 
respectively. In both RA cases and controls, 2% of the participants were treated surgically. 
Moreover, based on ACPA status in patients with RA, no significant differences were 
detected in any of the investigated treatment codes for periodontitis (minor- and major non-
surgical, as well as surgical periodontal treatment).  
Prevalence of periodontal diagnostic codes in relation to ACPA and RF status 
in patients with RA  
ACPA and RF are two important serological markers in RA. They are both part of the 
classification criteria for the disease [46], and have been associated with RA disease activity 
and/or severity [70-72, 79]. Moreover, both ACPA and RF antibodies have also been reported 
in non-RA subjects with periodontitis [87, 99, 100]. In Study I we investigated the prevalence 
of periodontitis in relation to ACPA and RF status in patients with RA. Patients with ACPA-
positive RA demonstrated no significant differences in the prevalence of any periodontal 
diagnostic codes (gingivitis, periodontitis, peri-implantitis, increased risk of periodontitis or 
increased risk of peri-implantitis) as compared to ACPA-negative RA (Table 3). In addition, 
there were no differences based on RF status (Table 3).  
 34 
 
 
Table 3. Prevalence of periodontal diagnostic codes in RA cases, in relation to ACPA and RF status 
Diagnosis 
ACPA- 
positive 
ACPA- 
negative  
RF-  
positive 
RF-  
negative  
 p value
†
 
Gingivitis  487 (33) 291 (34)  508 (34) 270 (33)  NS 
Increased risk of periodontitis  360 (25) 230 (27)  383 (25) 209 (25)  NS 
Increased risk of peri-implantitis  10 (0.7) 7 (0.8)  12 (0.8) 5 (0.6)   NS 
Periodontitis  487 (33) 268 (31)  498 (33) 259 (32)  NS 
Peri-implantitis  72 (5.0) 37 (4.3)  76 (5.0) 33 (4.0)  NS 
Results are presented as number (%). RA, rheumatoid arthritis; ACPA, anti-citrullinated protein antibody; RF, 
rheumatoid factor; NS, not significant. 
†
Statistical differences in prevalence of periodontal diagnostic codes between ACPA-positive and ACPA-negative or 
RF-positive and RF-negative RA cases. p value < 0.05 was considered statistically significant.  
 
To our knowledge, the Study I, which includes 1469 ACPA-positive and 852 ACPA-negative 
subjects with RA, is the largest study investigating the prevalence of periodontitis in relation 
to ACPA status in patients with established RA. The results, showing no association between 
ACPA antibody status and periodontitis in subjects with established RA, are consistent with 
other reports [115, 187, 188]. Recently, among 264 Korean patients with established RA, no 
correlation was found between ACPA titers and periodontitis, as estimated by PPD or CAL 
[115]. Moreover, Swiss patients with established RA (n = 52) showed no differences in serum 
levels of ACPAs based on the prevalence of periodontitis [187]. Additionally, in a Dutch 
population, although ACPA positivity was significantly associated with RA, the association 
with periodontitis was only borderline significant [188]. Similar results have recently been 
reported also in individuals with pre-RA and early RA, showing no association between the 
presence of periodontitis and APCA or RF status [173]. Nevertheless, there are also studies 
reporting a significant association between ACPA antibody status and periodontitis [113, 
114]. In a US population, the proportion of ACPA-positive RA patients with periodontitis 
was higher when compared to osteoarthritis controls (37% versus 26%), resulting in the OR 
of 1.59 (95% CI: 1.01 – 2.49, p < 0.043) [114]. RA patients with periodontitis have also been 
reported to have higher titer of both ACPA and RF as compared to RA subjects without 
periodontitis [113]. Moreover, RF-positive RA patients have been reported to have increased 
odds/OR for periodontitis and higher likelihood of being edentulous as compared to RF-
negative RA [114, 124]. 
Age and smoking habits are associated with increased prevalence of 
periodontitis 
Age and smoking are well known factors associated with the prevalence and severity of 
periodontitis [93, 189, 190]. Study I confirmed that both smoking (Table 4) and age increased 
the risk and prevalence of periodontitis both in healthy controls and in patients with RA. The 
prevalence of periodontitis increased significantly (p < 0.01) with age, but did not differ 
between RA cases and controls or based on gender or ACPA status. Moreover, logistic 
regression analysis showed that the risk of periodontitis increased with smoking habit after 
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adjusting for age, gender and residential area. In patients with RA, current smokers showed 
the highest risk for periodontitis (OR = 1.6, 95% CI: 1.2 – 2.0, p < 0.05), followed by ex-
smokers (OR = 1.4, 95% CI: 1.1 – 1.7, p < 0.05) and ever-smokers (OR = 1.4, 95% CI: 1.2 – 
1.7, p > 0.05) (Table 4). Similarly, the risk of periodontitis in healthy controls also increased 
by smoking habits (Table 4). The fact that we were able to detect and confirm the two well-
known risk factors for periodontitis, age and smoking [93, 189], supported the overall dataset 
and the results obtained in Study I. 
 
Table 4. Odds ratios (95% CI) for the association between periodontal 
diagnostic codes and smoking habits among RA cases and controls 
Diagnosis Current smokers 
 
Ex-smokers 
 
Ever-smokers 
RA cases 1.6 (1.2 - 2.0)
*
  1.4 (1.1 - 1.7)
*
  1.4 (1.2 - 1.7) 
Controls  1.8 (1.5 - 2.2)  1.1 (0.9 - 1.3)
*
  1.3 (1.1 - 1.5)
*
 
The results demonstrate subjects with at least one of the diagnostic codes; increased risk 
of periodontitis; increased risk of peri-implantitis; periodontitis or peri-implantitis. RA, 
rheumatoid arthritis. 
The odds ratios with a 95% confidence interval (95% CI) were adjusted for age, gender 
and residential area. 
*
p value < 0.05. 
 
Validation of the periodontal diagnostic codes in the DHR 
At the time when Study I was performed, the DHR was a new registry. To validate the 
periodontal diagnostic codes in the DHR, one hundred dental records from EIRA participants 
(50 RA and 50 controls) were screened. Overall the results from the dental records confirmed 
the diagnoses obtained from the DHR in 90% of all investigated participants. The positive 
predictive value (PPV), indicating the probability that periodontitis was present when the 
patient had diagnostic codes for periodontitis or peri-implantitis in the DHR, was 89% (95% 
CI: 78 – 95%). The sensitivity of the DHR was 77% (95% CI: 65 – 86%), which meant that 
77% of the participants with periodontitis were identified when using the periodontal 
diagnostic codes in the DHR. The specificity, indicating the accuracy of the DHR registry to 
correctly identify the patients that did not have periodontitis, was 71% (95% CI: 49 – 87%). 
The results above were in line with previous reports of the validity of both Swedish and other 
health databases, showing for example that the PPV ranges between 64 – 96% and the 
sensitivity between 51 - 90% [191-194]. Because the dental records in Study I were recruited 
from EIRA participants that self-reported having periodontitis, we were not able to report the 
negative predictive value for the DHR. The negative predictive value would have assessed 
the probability that periodontitis is not present when no periodontitis/peri-implantitis codes 
have been registered in the DHR.  
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STUDY II 
Effect of pre-existing periodontitis on experimental arthritis 
In Study II, experimental periodontitis was induced to assess the effects of pre-existing 
periodontitis on the initiation, rate of progression and severity of experimental arthritis (PIA). 
A severe localized periodontitis was established in all rats induced with experimental 
periodontitis (the PA group) prior to induction of experimental arthritis (week 8). In contrast, 
the animals in the group with experimental arthritis without pre-existing periodontitis (the A 
group), and healthy rats (without periodontitis or arthritis) did not show any clinical signs of 
periodontitis throughout the experimental period of 15 weeks. Macroscopic signs of 
inflammation, such as swelling and redness in limbs, appeared 2 weeks post PIA induction 
both in the PA and the A group (Figure 7). A period of remission, indicated by the decrease 
in mean arthritis score, occurred 4 weeks after the induction of PIA, as previously described 
[195]. Our results revealed also that here were no differences in the development or severity 
of arthritis based on the presence of pre-existing periodontitis, throughout the experiment 
(Figure 7). 
 
 
 
It has previously been suggested that pre-existing periodontitis, or infection with periodontal 
pathogens (such as P. gingivalis), may be associated with the development and severity of 
RA [19, 84]. In animal models, some studies have indicated that infection with periodontal 
pathogens (mainly P. gingivalis), administered subcutaneously or by oral gavage, can 
exacerbate the development and severity of experimental arthritis [84, 161, 163, 165]. 
Conversely, in agreement with our findings, others report no effect of periodontitis on the 
development or severity of experimental arthritis [159]. The inconsistent reports from 
different studies could potentially be due to different experimental models of periodontitis 
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Figure 7.
Overview of the arthritis disease severity as assessed by the mean arthritis score (±SE), and micro-CT
imaging of paws in arthritis rats with and without periodontitis.
PA, rats with experimental periodontitis and PIA; A, rats with PIA without periodontitis.
Figur .
The arthritis disease sev rity as asse sed by the mean arthritis score (±SE),  icro-CT
imaging of paws in arthritis rats with and without periodontitis.
PA, rats with experimental periodontitis and PIA; A, rats with PIA without periodontitis.
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and arthritis, or differences between strains of the periodontal pathogens administered. Most 
of the previous animal studies have been conducted in mice, where the size of the animals 
makes it difficult to obtain a more localized periodontal infection, and the administration of 
pathogens is therefore done subcutaneously or by oral inoculation/gavage [159, 161-163, 
165]. In Study II we used the rat model due to its larger size, which enabled us to induce a 
more local periodontitis by tying ligatures around the teeth (that promote bacterial adhesion) 
and combining them with application of local swabs containing periodontal bacteria. 
Moreover, the lack of effect of periodontitis on arthritis reported by us and others [159] could 
also potentially be due to the P. gingivalis strains used or potentially the amount of bacteria 
administered. Since different P. gingivalis strains may vary in their ability to promote bone 
loss [164] they could also differ in the ability to exacerbate arthritis. Most previous animal 
studies reporting an effect of periodontitis or P. gingivalis infection on arthritis development 
have used the strains W50 or W83. In Study II, P. gingivalis (strain CCUG 14449) was 
administered in combination with F. nucleatum because F. nucleatum is known to promote 
the colonization of P. gingivalis [196]. Moreover, an infection caused by the combination of 
these two bacteria is known to induce a stronger inflammatory response as compared to either 
pathogen alone [197]. The discrepancies in the reported results could also be due to different 
models of experimental arthritis. In studies reporting a more severe arthritis as a result of co-
induction with periodontitis, mostly collagen-induced arthritis (CIA) or collagen antibody-
induced arthritis (CAIA) have been used [161-163, 165]. In Study II, we used the PIA model 
because it is a well-established experimental model of arthritis that closely mimics RA, 
including characteristics such as the presence of RF, symmetrical involvement of peripheral 
joints as well as cartilage and bone destruction [195]. In contrast to CIA and CAIA, which 
induce an acute arthritis, the PIA model triggers a chronic relapsing form which makes it 
suitable for studying different phases of the disease [195]. By using the PIA model in 
combination with the extended experimental period allowed us to investigate the effect of 
experimental periodontitis during both active and chronic forms of arthritis.  
Effect of pre-existing periodontitis on arthritis associated acute phase proteins  
-1-AGP and CRP are two acute phase proteins associated with disease activity and degree 
of disability in patients with RA [198, 199]. The levels of CRP are part of the ACR 
classification criteria for RA disease [46], and -1-AGP, described as a major acute phase 
protein in both humans and animals (e.g. rats and mice), has been suggested as a useful 
biochemical marker of RA disease activity [199, 200]. During the first 8 week of Study II, at 
the time of the periodontitis induction, the levels of plasma -1-AGP were comparable in rats 
with and without periodontitis. After PIA induction there was a rapid increase in -1-AGP, 
with a peak around 3 weeks post immunization. During the time of remission, indicated by 
the mean arthritis score, the levels of -1-AGP decreased. There were no significant 
differences in plasma -1-AGP between the groups, only a tendency (p = 0.07) towards 
higher levels in the group with periodontitis. A similar pattern was seen for the plasma levels 
of CRP. After PIA induction the levels of CRP increased in both the PA and the A group, 
only to decrease again following the clinical signs of remission. There were no significant 
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differences in CRP concentrations at baseline, after PIA induction or at endpoint based on the 
pre-existence of periodontitis.   
Plasma levels of both -1-AGP and CRP are typically elevated as a result of infection, 
inflammation or injury [200, 201]. Although the levels of both -1-AGP and CRP have 
previously been investigated in rats with arthritis [202, 203], Study II was to our knowledge 
the first study reporting the plasma levels of -1-AGP in rats induced with both periodontitis 
and arthritis. In a previous study the levels of -1-AGP have been shown to correlate with the 
development of arthritis in rats with PIA [202]. In our study, the levels of both -1-AGP and 
CRP reflected the clinical manifestations of the disease, but did not significantly differ based 
on the existence or absence of periodontitis.   
Effect of pre-existing periodontitis on levels of inflammatory mediators in 
experimental arthritis 
In the pathogenesis of RA and periodontitis, both cytokines and chemokines act as important 
signal mediators [6, 35]. By activating immune cells, fibroblasts and osteoclast as well as 
releasing proteolytic enzymes, these signal mediators collectively contribute to the 
characteristic bone and tissue destruction seen in RA and periodontitis [6, 35]. Interestingly, 
in Study II the mean levels of the investigated cytokines (IL-1, IL-1β, IL-2, IL-4, IL-5, IL-7, 
IL-10, IL-12, IL-13, IL-17, IL-18, TNF-, RANTES, GM-CSF, M-CSF, MCP-1, GRO/KC, 
MIP-3, EPO and VEGF) were increased in rats with both periodontitis and PIA, as 
compared to arthritis affected animals without pre-existing periodontitis. However, none of 
the differences reached statistical significance.  
Several of the cytokines measured in Study II have previously been reported in periodontitis 
and RA, acting as either anti-inflammatory (such as IL-4 and IL-10) or pro-inflammatory 
(such as IL-1, IL-12, IL-17, IL-18 and TNF-) mediators during inflammatory conditions [6, 
204]. Chemokines such as MCP-1 and RANTES can induce chemotaxis and attract immune 
cells to the affected inflamed tissues [6]. Together these cytokines and chemokines play a 
crucial role in bone and tissue destruction [6]. The constantly higher plasma levels of the 
investigated cytokines in the PA group could potentially suggest that there might be an 
increased activation of the immune system as a result of the additional inflammatory stimuli 
due to periodontitis.  
Effect of pre-existing periodontitis on antibody levels against RgpB and 
citrullinated PPAD peptides 
Rats with pre-existing periodontitis showed elevated plasma levels of antibodies against 
arginine-gingipain B (RgpB) protease, an important virulence factor for periodontitis. In the 
PA group, 89% of the animals had antibodies against RgpB, whereas both group A (without 
pre-existing periodontitis) and healthy control animals tested negative for RgpB antibodies. 
Furthermore, the rats in the PA group also showed significantly (p < 0.05) increased plasma 
levels of antibodies against CPP3, a PPAD citrullinated peptide as compared to the 
periodontitis free animals. In contrast, there were no differences between the groups in 
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antibody levels against the uncitrullinated PPAD peptide, the RPP3, suggesting that the 
increased antibody response against CPP3 was citrulline-specific and not directed against 
other parts of the peptide. 
The RgpB is one of P. gingivalis major virulence factors and is also important for P. 
gingivalis ability to citrullinate proteins [174]. These enzymes cleave protein at arginine 
residues before a citrullination by PPAD can occur [19, 174].  In patients with RA, the 
antibody levels of RgpB have been shown to be elevated as compared to non-RA controls 
[205]. To our knowledge, Study II is the first report showing the levels of RgpB in animals 
with experimental arthritis and pre-existing periodontitis. Our results indicate that local oral 
infection with P. gingivalis was able to stimulate an immune response in the periodontitis 
challenged animals with PIA (PA group), as compared to animals with PIA without pre-
existing periodontitis (A group) and healthy controls.  
The association between RA and periodontitis has been suggested to, at least in part, to be 
due to P. gingivalis´ ability to secrete a citrullinating enzyme (PPAD) [87]. In support of this 
hypothesis, in arthritic mice inoculation with P. gingivalis has been demonstrated to cause 
significantly more cartilage and bone destruction compared to animals without P. gingivalis 
infection or even in animals infected with a PPAD deficient strain of P. gingivalis [162, 165]. 
Furthermore, non-significantly increased levels of ACPAs in serum have been detected in 
mice with both periodontitis and arthritis [162]. Significantly elevated levels of ACPAs have 
been reported following a subcutaneous infection with P. gingivalis in mice [163]. Study II 
was the first study reporting higher antibody levels against also a PPAD citrullinated peptide 
in arthritic animals with pre-existing periodontitis. It is however possible that the antibodies 
detected in previous studies might not be citrulline-specific, as these antibodies might be 
directed against some other part of the peptide rather than the citrulline-specific part [206]. 
Therefore, in Study II we also investigated the levels of antibodies against the non-
citrullinated controls peptides (RPP3), showing no differences in these antibodies between 
rats with and without periodontitis. Taken together these results indicate that pre-existing 
periodontitis can induce a systemic antibody response against citrullinated peptides derived 
from PPAD, in rats with experimental arthritis. In patients who are positive for P .gingivalis, 
PPAD has been suggested to be responsible for citrullinating proteins in the gingival tissue, 
breaking the immune tolerance and thus contributing to the production of ACPAs [24, 87]. 
The host immune response, directed against PPAD citrullinated peptides, may then target 
host-citrullinated proteins present in the joint, and thereby contribute to the initiation and the 
autoantibody response in RA [24, 87, 207]. 
 
STUDY III 
To further explore the possibility of citrullination in periodontitis-affected gingival tissue, the 
presence of citrullinated proteins and expression of citrullinating PAD enzymes (PAD2 and 
PAD4) were investigated in gingival tissue biopsies from patients with periodontitis and 
healthy controls. 
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Presence of citrullinated proteins in gingival tissue from patients with and 
without periodontitis 
In Study III a monoclonal antibody (F95) was used for detection of citrullinated proteins 
[101]. The advantages when using monoclonal antibodies is that they produce less 
background staining and are less likely to cross-react with other proteins that are not of 
interest, as they only target one epitope per antigen [208]. In patients with periodontitis, 
increased staining of citrullinated proteins was observed in gingival connective tissue (80%, 
12 out of 15 samples), as compared to the gingival connective tissue of healthy controls 
(27%, 4 out of 15 samples) (p < 0.01). With regard to gingival epithelium, there were no 
differences in the expression of citrullinated proteins in patients with and without 
periodontitis. The citrullinated proteins were detected mainly in association with 
inflammatory cells, fibroblast-like cells and the extracellular matrix of the gingival 
connective tissue, and were not correlated with the presence of P. gingivalis. In line with our 
results, higher levels of citrullinated proteins have been reported in inflamed gingival tissue 
collected from 29 patients undergoing periodontal surgery, when compared to 11 subjects 
without gingival inflammation [98]. The expression of these citrullinated proteins was mainly 
localized to the endothelial cells, fibroblasts and infiltrating inflammatory cells which are 
predominantly expressed in the connective gingival tissue, in agreement with our results [98, 
209]. Likewise, in stroma from patients with periodontitis citrullinated proteins were detected 
in 80% (n = 12) of the periodontitis affected samples as compared to 33% (n = 2) in non-
inflamed control tissues, when stained with polyclonal antibodies (AB5612) [101]. Taken 
together the results from these studies indicate that periodontitis may lead to the production of 
certain types of citrullinated proteins that are expressed in the gingival connective tissue.  
Presence of PAD2 and PAD4 in gingival tissue from patients with and without 
periodontitis 
Similar to the staining of citrullinated proteins, the expression of PAD2 and PAD4 enzymes 
were also significantly (p < 0.01) higher in the connective tissue from periodontitis affected 
individuals, compared to controls. In the gingival epithelium, no differences were reported in 
PAD2 or PAD4 enzymes. No correlation was found between the presence of P. gingivalis 
and the expression of the PAD2 or PAD4 endogenous enzymes. 
The PAD2 and PAD4 enzymes are present in synovial tissue from patients with RA, and 
citrullination of proteins in the synovium has been attributed to these enzymes [210, 211]. In 
gingival tissue, in agreement with our findings, significantly higher expression of PAD2 and 
PAD4 enzymes have been detected in patients with periodontitis as compared to non-
periodontitis controls [98]. The presence of these enzymes indicates the potential for 
citrullination in gingival tissue during periodontitis [98]. However, since the periodontitis 
associated pathogen P. gingivalis can invade gingival tissue [212], the increase of 
citrullinated proteins in periodontal tissue, detected in the present study and others, might 
have been produced as a result of PPAD rather that PAD enzymes [98]. In our study, there 
was no correlation between the citrullinated proteins and the presences of P. gingivalis in 
gingival tissue. Nevertheless, we did not investigate the expression of PPAD in the biopsies. 
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Unfortunately, there are no commercially available antibodies against PPAD and the presence 
of this bacterial enzyme in gingival tissue has therefore not yet been investigated. Even so, 
the results of increased expression of the important PAD enzymes and presence of 
citrullinated proteins in gingival tissue from patients with periodontitis suggest that 
citrullination may indeed present in the gingiva during periodontitis.  
 
STUDY IV 
Severity of periodontitis in patients with RA, in relation to ACPA and RF status 
To evaluate the severity of periodontitis in patients with RA, 40 subjects with established RA 
underwent a full-mouth dental examination performed by a single examiner. The clinical and 
radiographic examinations revealed that the majority of the participants (75%, n = 30) had 
moderate to severe periodontitis. These RA patients had significantly higher PPD, CAL, 
number of furcation involved, mobile and missing teeth as compared to RA patients with no 
or mild periodontal disease (n = 10). APCA positivity was significantly (p = 0.032) more 
frequent in patients with moderate/severe periodontitis (86%) compared to the group with 
no/mild periodontitis (50%). Although RF positivity also seemed more frequent in patients 
with moderate/severe periodontitis (73% versus 50%), these differences were not statistically 
significant. Moreover, there were no between-group differences with regard to plaque or 
bleeding index based on periodontitis severity or ACPA status. Patients with moderate/severe 
and no/mild periodontitis were comparable regarding gender distribution, RA disease 
duration, type of RA medication used, comorbidities (such as diabetes, cardiovascular disease 
etc), body mass index (BMI), alcohol consumption, education and place of birth. In contrast, 
based on periodontitis severity, only age and smoking habits differed between the groups, in 
line with previous reports [93, 213]. Patients with no/mild periodontitis were significantly 
younger (mean age 50 versus 64 years, p = 0.010) and the majority of patients in this group 
were never smokers (60% versus 17%, p = 0.014) compared to subjects with moderate/severe 
periodontitis.  
More severe forms of periodontitis, including increased PPD and CAL, have previously been 
reported in German, Iraqi, Indian, Australian and American populations with RA when 
compared to osteoarthritis or healthy controls [108, 117, 120-123, 128]. In Study I, we 
reported that Swedish patients with established RA showed no differences in the prevalence 
of periodontal diseases, when compared to healthy controls without RA. However, in that 
study we were not able to investigate the severity of periodontitis based on clinical 
measurements such as PPD and CAL. Therefore, in Study IV a clinical assessment of 
periodontitis severity was performed in patients with established RA. Our results indicate that 
more severe forms of periodontitis are frequent in patients with RA, which is in line with 
previous published data [111, 116]. Moreover, ACPA-positive RA was also more common in 
patients with moderate/severe periodontitis compared to no/mild periodontal disease. Similar 
associations between periodontitis severity and ACPA status or increased ACPA levels have 
been observed in American subjects with RA [116, 128]. Nevertheless, some studies do not 
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report significant association between periodontitis severity and ACPA-positive RA [115, 
188]. For example, in a recent study including 264 patients with RA only bleeding on 
probing, but not PPD or CAL, was associated with ACPA status [115]. Also, when it comes 
to the association between RF status and periodontitis severity the results from previous 
studies are inconsistent. Some studies report an association between the prevalence and 
severity of periodontitis and increased RF antibody titers [113, 116], while other studies 
report a lack of association [115, 118]. The inconsistent results regarding periodontitis and 
seropositive RA may be due to differences between study populations such as ethnicity, or 
differences in classification criteria used to diagnose periodontitis. Moreover, it is also 
possible that an association between periodontitis and RA, or seropositive RA, exists only in 
susceptible individuals such as carriers of specific genes (e.g. HLA-DRB1 SE), or in 
subpopulations exposed to factors not investigated in these studies (e.g. other pathogens or 
environmental factors).  
RA disease activity in relation to periodontitis severity 
Several indicators of RA disease activity were investigated in patient with no/mild and 
moderate/severe periodontitis. There were no significant differences in the DAS28 score 
reported by the rheumatologists, the patients self-assessed HAQ score or the levels of the 
acute phase protein CRP in serum, saliva or GCF, based on periodontitis severity. 
Importantly, the two groups of patients were comparable for several potential confounding 
factors that could have affected the results such as RA disease duration, type of RA 
medication used and comorbidities.  
In agreement with our results the lack of association between periodontitis severity and RA 
disease activity has been reported in other studies [118, 121, 123]. In both American (n = 50) 
and Indian populations with RA (n = 100), no association was found between DAS28 score 
and periodontitis severity [121, 123]. Moreover, serum levels of the acute phase proteins CRP 
and ESR have been reported to be comparable between RA patients with gingivitis and RA 
subjects with periodontitis [118]. In contrast to our results, several studies do report an 
association between loss of alveolar bone and RA disease activity and severity [114, 116, 
119, 129]. In one cohort consisting of 287 American subjects with RA, tree studies have 
reported a significant (p < 0.05) correlation between periodontitis diagnosis/alveolar bone 
loss/self-reported “loose teeth” and increased DAS28 score, HAQ score or tender/swollen 
joint count [114, 116, 129]. In addition, higher DAS28 score was also reported in a Dutch 
population of RA subjects with severe periodontitis when compared to patients with moderate 
or no periodontal disease [119]. However, in this study the use of RA medication was not 
evaluated [119]. RA medications have previously been shown to improve periodontal 
parameters such as CAL and PPD [148, 154, 214]. It is therefore important to include the use 
of RA medication when investigating the associations between RA and periodontitis severity. 
In Study IV, we did account for RA medication, showing no differences in the prevalence of 
different types of medications based on the severity of periodontitis, which is in line with 
previous reports [114, 116]. However, it is possible that patients in the two groups with 
no/mild and moderate/severe periodontitis respond differently to RA medications. Moreover, 
 43 
 
different subtypes of RA medications, such as TNF- blockers and anti-IL-6 receptor 
antibodies (subtypes of biological DMARDs), could potentially differ in their ability to affect 
periodontitis severity. Therefore, accounting for subtypes of RA medications may provide 
additional information about potential differences in periodontitis severity between RA 
patients, not identified here. However, to be able to study such subdivisions of RA 
medications, larger cohorts are needed in order to have a sufficient number of patients to 
compare in different subgroups.  
Prevalence of P. gingivalis in patients with RA, in relation to periodontitis 
severity and ACPA status 
The reigning hypothesis of the link between periodontitis and RA proposes that an 
association may be due to P. gingivalis ability to secrete a citrullinating enzyme, resulting in 
citrullination of proteins potentially contributing to the production of ACPAs. Therefore, in 
Study IV, we also investigated the prevalence of P. gingivalis in patients with RA, in relation 
to ACPA status. The majority (60%) of the investigated RA subjects tested positive for P. 
gingivalis in subgingival plaque samples. There were, however, no significant differences in 
the prevalence of P. gingivalis based on ACPA status, or based on the presence/severity of 
periodontitis. The prevalence of P. gingivalis obtained in our study corresponded to the 
prevalence of P. gingivalis previously reported in patients with RA (47% - 67%) [114, 119]. 
Similar to our results, P. gingivalis was not associated with autoantibody status (ACPA or 
RF) in Southern European subjects at risk of RA, or with the presence of periodontitis in 
Dutch patients with established RA [180, 187]. On the other hand, an association between the 
prevalence of subgingival P. gingivalis and increased ACPA levels in serum has been 
reported in an American cohort of RA subjects [114].  
Inflammatory mediators in serum, saliva and GCF of patients with RA, in 
relation to periodontitis severity 
In RA subjects with moderate/severe periodontitis the levels of several inflammatory 
mediators were increased either in serum, saliva or in GCF, as compared to RA with no/mild 
periodontal disease. In serum the increased inflammatory mediators were APRIL, sCD30 and 
gp130, in GCF the levels of INF-2, IL-19, IL-26, MMP-1 and sTNF-R1 were elevated, 
whereas in saliva only APRIL was increased. Interestingly, the levels of a proliferation-
inducing ligand (APRIL) were up-regulated in both serum and saliva samples of RA subjects 
with moderate/severe periodontitis. APRIL is a cytokine that can stimulate the proliferation 
and maturation of B-cells [215, 216]. B-cells are involved in autoimmune diseases through 
different mechanisms including the secretion of antibodies (such as ACPAs) and presentation 
of autoantigens [217, 218]. APRIL could therefore potentially be involved also in the RA-
periodontitis association, although our observation needs to be confirmed in other studies. 
Even though, in serum, increased levels of APRIL have previously been reported in patients 
with RA [216] and in patients with periodontitis [219] this is the first study reporting 
increased levels of APRIL based on periodontitis severity in subjects with RA.   
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STRENGTHS AND LIMITATIONS (STUDIES I - IV) 
When interpreting the results of a study it is important to consider the studies design as it may 
affect the interpretation [220]. For example, when investigating the association between an 
exposure (e.g. a disease) and its effect on a population, factors such as bias (a systematic error 
of measurements due to faults in the studies design or conduct) can affects the estimated 
statistic, giving an incorrect assessment of the association [221, 222]. Flaws in the design are 
an issue in virtually all studies [222]. The designs of the studies included in this thesis have 
several strengths, but also some limitations, which are discussed below.  
Study I 
Study I was an observational case-control study where the association between periodontitis 
and RA was evaluated retrospectively by linking the information from two registries. The 
advantages of observational studies include relatively fast execution of the study and the 
opportunity to address a broad range of questions [222]. Moreover, using a registry study 
design allowed us to investigate the association between periodontitis and RA in a large 
population, thereby increasing the power of the analysis and the chance to detect an 
association if there was one. In fact, Study I is to our knowledge the largest study 
investigating the association between ACPA status and periodontitis in patients with RA. In 
addition, the well-defined population of the EIRA registry is another strength of this study. 
All RA cases in the EIRA registry were diagnosed by a rheumatologist following 
international consensus criteria for RA. Moreover, all controls were matched to RA cases for 
gender, age and residential area and were recruited at the same time as the RA cases. 
Furthermore, information was also available regarding important factors such as education 
level and smoking habits that could have affected the results. Because both low education 
level and smoking are associated with the prevalence and risk of periodontitis [93, 223], 
taking these factors into account is a strength in Study I. However, it is important to note that 
in this study we did not investigate whether periodontitis is a risk factor for RA or ACPA-
positive RA before the onset of disease, since the RA patients included in this study had 
established RA at the time when DHR was initiated. Instead, Study I investigated whether 
there was an association between the presence of periodontitis and established RA disease. 
A limitation of Study I was the lack of information about some potential confounding factors 
that could have affected the results. For example we did not have information about 
comorbidities, including diabetes mellitus that has been associated with increased risk of both 
periodontitis and RA [23, 38]. We also lacked information about RA disease activity and type 
of RA medication used at the time of periodontal diagnosis in the DHR. Anti-inflammatory 
medication used in treatment of RA has been proposed to decrease the progression of 
periodontitis and may have masked an association [148, 224]. Furthermore, when 
investigating the association between the prevalence of periodontitis and RA in relation to 
age, the number of participants in the younger age groups was low. Still, despite these 
limitations, two well-known risk factors/indicators for periodontitis (smoking and age) were 
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confirmed to increase the risk and prevalence of periodontitis in our cohort, supporting the 
dataset and the overall results of the study.  
Study II 
The animal study was an experimental study designed to assess the effect of an intervention, 
in this case the pre-existence of periodontitis on the development and severity of 
experimental arthritis. In this study the animals were randomly assigned to the different 
experimental groups and followed for 15 weeks. The long experimental period allowed us to 
assess the effects of pre-existing periodontitis not only in active arthritis but also during a 
period of remission. Additionally, when investigating the level of antibodies against PPAD 
citrullinated peptides we included a non-citrullinated control (RPP3) to ensure the specificity 
of the result. Because it is possible that antibodies may bind to other parts of the protein and 
not necessarily to the citrulline-specific part, the investigation of antibodies against RPP3, the 
uncitrullinated PPAD peptide, is an important strength of Study II.  
The low number of animals, especially in the healthy control group is, however, a limitation 
of this study. We decided to assign the majority of the animals to the two experimental 
groups (the periodontitis-arthritis and arthritis without periodontitis) in order to increase the 
sample size and the potential to detect significant difference between these groups, and to still 
minimize the number of animals in the study for ethical and practical reasons. Additionally, 
because the objective of the study was to investigate the effect of periodontitis on arthritis, 
and not the effect of arthritis on periodontitis, we did not include an experimental group with 
periodontitis only. Another possible limitation of Study II could be the choice of the arthritis 
model, as the experimental arthritis used in this study (PIA) may simply have been too strong 
to demonstrate any additional effects that periodontitis may have had. However, other 
arthritis models such as CIA, widely used in studies investigating the association between 
periodontal pathogens and arthritis are comparable or more severe than the PIA model in rats 
[225]. Although it would have been possible to inject a lower dose of pristane, we decided to 
induce PIA using a standardize protocol thereby decreasing the risk of variability and 
increasing the chance to detect significant differences [226].  
Study III 
In Study III, we used a case-control study design were the gingival biopsies were collected 
from patients with the outcome of interest (here periodontitis) and compared to the gingival 
tissue from healthy controls. The groups with and without periodontitis were comparable 
with respect to gender and age distribution, eliminating these factors as potential 
confounders. Another strength of Study III was the blinded investigators evaluating the 
immunohistological stainings of the gingival tissues. None of the tree independent examiners 
had information about the periodontal status of the patients from whom the biopsies were 
collected, thus minimizing the risk of bias due to preconceived expectations [222]. 
A potential limitation of Study III was that we were not able to investigate the presence of the 
PPAD citrullinating enzyme in the biopsies, as there are no commercially available antibodies 
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for the staining against PPAD. This makes it difficult to speculate about the specific origin of 
the citrullinated proteins detected in the biopsies in this study, as they could potentially have 
been produced as a result of citrullination by PPAD rather than PAD enzymes. Moreover, it 
would have been interesting to investigate the presence of citrullinated proteins and PAD 
enzymes also in gingival biopsies from RA subjects with and without periodontitis, as well as 
patients at risk of RA. However, we did not have accesses to gingival tissues from these 
patients preventing us from investigating the relationship between periodontitis and the 
presence of citrullinated proteins/citrullinating enzymes in the gingiva of subjects with RA.   
Study IV 
Study IV was a pilot study with a cross-sectional study design. Cross-sectional studies are 
used when the purpose is to report the prevalence of the outcome of interest (e.g. periodontitis 
severity) or to describe a population at a specific time point [227]. The cross-sectional studies 
are a type of observational studies where the risk factors are measured at the same time as the 
outcome [222]. For example, in Study IV smoking habits were recorded at the same time as 
the severity of periodontitis in RA. The well-characterized data set is a strength of Study IV, 
containing information about several potential confounding factors for periodontitis and RA 
including RA disease duration, type of RA medication, comorbidities, BMI, smoking and 
alcohol habits, education level and place of birth. Moreover, the gender distribution among 
patients with RA reflected that of the general population indicating a representative data set.  
There are however some limitations in Study IV. Because the main focus of this study was to 
investigate the severity of periodontitis in patients with RA no healthy controls were 
included. Moreover, the low sample size, especially in the group with no/mild periodontitis, 
makes it difficult to draw definite conclusions. In addition, due to the lack of information 
about the durations of different RA medications, we cannot exclude that this could have had 
an impact on for example the levels of inflammatory mediators analyzed in this study [228].  
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CONCLUDING REMARKS 
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his section summarizes the main finding of the thesis, including a brief discussion of 
potential  future perspectives on the relationship between periodontitis and RA.  
 
MAIN FINDINGS 
 
 The prevalence of periodontitis in Swedish patients with established RA, included in 
the EIRA study, was not increased compared to matched healthy controls. Among 
subjects with RA, no differences in prevalence of periodontitis were detected based 
on ACPA or RF antibody status. 
 
 Clinical investigations of oral health conditions revealed that moderate/severe 
periodontitis was common in patients with established RA. In addition, ACPA 
positivity was significantly more frequent in RA subjects with moderate/severe 
periodontitis compared to no/mild periodontal disease. There were no differences in 
RA disease duration or disease activity or type of RA medication based on 
periodontal diagnosis. 
  
 The levels of several inflammatory mediators were significantly different in serum, 
saliva and GCF of RA patients with moderate/severe periodontitis compared to those 
with no/mild disease. The levels of the proliferation factor APRIL, involved in B-cell 
survival and maturation, were significantly increased in both serum and saliva of 
RA patients with moderate/severe periodontitis. 
 
 Increased presence of citrullinated proteins and expression of PAD2 and PAD4 
enzymes was detected in gingival connective tissue from patients with periodontitis as 
compared to periodontally healthy controls. The presence of P. gingivalis did not 
correlate with PAD2 or PAD4 expression or with the presence of citrullinated 
proteins.  
 
 In animals with pristane-induced arthritis, the pre-existence of periodontitis resulted 
in increased levels of antibodies against a citrullinated peptide derived from PPAD. 
Rats with arthritis and pre-existing periodontitis also generated higher systemic 
immune response and antibody levels against RgpB, an important virulence factor of 
P. gingivalis. The development and severity of pristane-induced arthritis was not 
affected by the pre-existence of periodontitis.  
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FUTURE PERSPECTIVES 
The relationship between periodontitis and RA has received increased attention the last two 
decades due to the hypothesis that oral infections by periodontal bacteria may play an 
important role in the pathogenesis of RA, as well as studies indicating that patients with RA 
may have an increased risk of periodontitis. However, many aspects of this association still 
remain unclear and warrant further investigation into the temporal relationship, the 
predisposing risk factors, the mechanisms involved, as well as the effects of both periodontal 
treatment and RA medications in the association between these two diseases. 
The results from our and other studies indicate that periodontitis prevalence may not be 
increased in all patients with RA, since some studies including those investigating large 
population do not detect an association between these two diseases. Although a recent 
systematic review concluded that patients with RA have a slightly increased risk of 
periodontitis when estimated by markers of periodontitis severity (PPD and CAL) [140], it is 
possible that this association may be true mainly for specific subtypes of RA and/or for 
susceptible individuals. For example, in patients with RA primarily susceptible individuals 
carrying the HLA-DRB1 SE alleles appear to generate an immune response against 
citrullinated peptides [24]. Therefore, the inconsistent results between different studies could 
potentially be due to differences in study population such as genetic background, 
environmental factors or the composition of the oral microbiota. Thus, the relationship 
between periodontitis and RA warrants further investigation into the predisposing 
environmental and genetic risk factors, as well as the immune-inflammatory mechanisms 
linking periodontitis with RA. 
RA medications have been suggested to be potential confounding factors masking an 
association between periodontitis and RA by reducing periodontal inflammation [229]. In 
light of the results from our pilot study however, only the type of RA medication alone may 
not entirely explain a potential lack of association, as our results showed no differences with 
regard to type of RA medications taken by RA patients with moderate/severe and no/mild 
periodontitis. Another explanation could be that patients respond differently to RA 
medications not only with respect to RA [230] but also regarding periodontitis, or that 
different subtypes of DMARDs/biological DMARDs may affect periodontitis severity 
differently. In our study, we were not able to investigate the association between different 
subtypes of DMARDs/biological DMARDs and the severity of periodontitis. Thus, future 
large prospective epidemiological studies, accounting for subtypes of different RA 
medications as well as the duration of treatment, may give further insight into a possible 
relationship between RA medication and the prevalence/severity of periodontitis. 
The periodontal bacteria P. gingivalis may potentially be involved in the underlying 
mechanisms linking periodontitis to RA, as supported also by the results from our animal 
experiments. By inducing a systemic immune response to citrullinated peptides, P. 
gingivalis/PPAD enzyme could be involved in generating an RA specific immune response 
resulting in ACPA production. However, some studies also report a lack of association 
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between P. gingivalis and ACPA production [180, 187]. Moreover, recently the periodontitis 
associated pathogen A. actinomycetemcomitans has also been implicated in RA specific 
autoimmunity, due to its ability to trigger a dysregulated activation of citrullinating enzymes 
in neutrophils [104]. In this context, future research could benefit from studies investigating 
the microbiota profile in RA patients with and without periodontitis, conducted in large 
cohorts.  
Given that ACPA status may be associated with periodontitis severity, future research on the 
association between periodontitis and RA should also focus on investigating the potential 
beneficial effects of periodontal treatment in patients with RA. Previous studies have 
indicated that non-surgical periodontal treatment in RA patients with periodontitis may 
reduce RA disease activity [142, 143, 145, 146, 148, 149]. However, all of these studies have 
a short follow-up time (6 weeks to 6 months) and the results should therefore be confirmed 
by additional studies conducted over a longer period of time. Moreover, longitudinal studies 
following patients at risk of RA as well as patients with newly diagnosed RA are also 
warranted to explore the role of periodontitis/periodontal infection in the development of RA. 
To sum up, further research is needed including studies on the mechanisms linking 
periodontitis and RA before a causative relationship between periodontitis and RA can be 
established [107, 126, 140, 231]. Future research on the relationship between these two 
diseases should also focus on investigating the predisposing genetic and environmental risk 
factors for this association, the oral microbiota profile, subtypes of different RA medications 
and duration of these therapies, as well as the effects of periodontal treatment in patients with 
RA. Moreover, additional studies with focus on patients at risk of RA as well as newly 
diagnosed RA cases may also provide more insight into this relationship. 
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